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Abstract
As a follow-up to the re-evaluation of starch sodium octenyl succinate (SSOS; E 1450), the Panel on
Food Additives and Flavourings (FAF) was requested to assess the safety of SSOS (E 1450) when used
in food for infants below 16 weeks of age for food categories 13.1.5.1 and 13.1.1 and to address the
data gaps identified during the re-evaluation of the SSOS (E 1450). The process involved the
publication of a call for data. The Panel considered it feasible to amend the specifications based on
the analytical evidence submitted. In the call for data, clinical trials were submitted to support the safe
use in this age group. In addition, the report of a postnatal piglet study was provided. Due to the low
internal validity of the clinical studies, the Panel concluded that a reference point could not be derived
from them. The Panel noted that the uncertainty surrounding the results of the piglet study precludes
deriving a reference point from this study. On the other hand, both data sources did not clearly
indicate an adverse effect due to SSOS (E 1450). Given the available data, the Panel concluded that at
use levels of SSOS in food for infants below 16 weeks within the range reported in the clinical studies
(up to 2,725 mg/kg body weight (bw) per day), there is no indication for safety concern and reiterated
the conclusion of the Panel on Food Additives and Nutrient Sources added to Food (ANS) that there
was no need for a numerical acceptable daily intake (ADI). When extrapolating this conclusion to the
safety assessment of the food additive when used in food categories (FCs) 13.1.5.1 and 13.1.5.2 in
food for infants above 16 weeks of age and young children, the Panel considered that there is no
indication for safety concern also for these uses within the range reported in the clinical studies.
© 2020 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
Keywords: Starch sodium octenyl succinate, E 1450, food additive, infants
Requestor: European Commission
Question number: EFSA-Q-2018-00102
Correspondence: fip@efsa.europa.eu
* This opinion was first adopted by the FAF Panel on 25 September 2019, as reflected in the minutes of the FAF Plenary Meeting
of 24-26 September 2019: http://www.efsa.europa.eu/sites/default/files/event/190924-m.pdf. However, the adopted version
was withdrawn prior to publication (see https://www.efsa.europa.eu/sites/default/files/event/191112-m.pdf) and the current
version was adopted by the FAF Panel on 30 June 2020.
EFSA Journal 2020;18(8):5874www.efsa.europa.eu/efsajournal
Panel members: Maged Younes, Gabriele Aquilina, Laurence Castle, Karl-Heinz Engel, Paul Fowler,
Maria Jose Frutos Fernandez, Peter F€urst, Rainer G€urtler, Ursula Gundert-Remy, Trine Husøy, Melania
Manco, Wim Mennes, Peter Moldeus, Sabina Passamonti, Romina Shah, Ine Waalkens-Berendsen,
Matthew Wright and Detlef W€olfle.
Note: The full opinion will be published in accordance with Article 8 of Regulation (EU) No 257/2010
once the decision on confidentiality will be received from the European Commission.
Suggested citation: EFSA FAF Panel (EFSA Panel on Food Additives and Flavourings), Younes M,
Aquilina G, Castle L, Engel K-H, Fowler P, Frutos Fernandez MJ, F€urst P, G€urtler R, Husøy T, Manco M,
Mennes W, Moldeus P, Passamonti S, Shah R, Waalkens-Berendsen I, W€olfle D, Wright M, Dusemund
B, Mortensen A, Turck D, Barmaz S, Rincon AM, Smeraldi C, Tard A, Vianello G and Gundert-Remy U,
2020. Opinion on the re-evaluation of starch sodium octenyl succinate (E 1450) as a food additive in
foods for infants below 16 weeks of age and the follow-up of its re-evaluation as a food additive for
uses in foods for all population groups. EFSA Journal 2020;18(8):5874, 60 pp. https://doi.org/10.2903/
j.efsa.2020.5874
ISSN: 1831-4732
© 2020 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited and no
modifications or adaptations are made.
The EFSA Journal is a publication of the European Food
Safety Authority, an agency of the European Union.
Opinion on the re-evaluation of starch sodium octenyl succinate (E 1450)
www.efsa.europa.eu/efsajournal 2 EFSA Journal 2020;18(8):5874
Summary
In accordance with Regulation (EU) No 257/2010, the European Food Safety Authority (EFSA) is
currently re-evaluating the safety of food additives already permitted in the Union before 20 January
2009 and issuing scientific opinions on their safety when used in food as per Annexes II and III to
Regulation (EC) No 1333/2008. The risk assessment approach followed in the re-evaluation has not
covered the use of food additives in food for infants below 12 weeks of age so far. Additionally, while
re-evaluating the safety of food additives referred to above, EFSA identified some concerns, namely
(1) data gaps that have triggered recommendations in the (to be) published scientific opinions; and/or
(2) data gaps that have increased uncertainties linked to the risk assessment and/or which prevented
the panel from concluding on some aspects of it.
On 31 May 2017, EFSA published a guidance on the risk assessment of substances present in food
intended for infants below 16 weeks of age, thus enabling EFSA to assess the safety of food additive
used in food for infants below this age. The age up to 16 weeks was selected in the guidance because
infants are exposed to formula feeding until this age as the only source of food since complementary
feeding is not supposed to be introduced before.
As follow-up of the above, this opinion addresses the data gaps previously identified during the re-
evaluation of starch sodium octenyl succinate (SSOS; E 1450) including the risk assessment of starch
sodium octenyl succinate (E 1450) for the use as food additive in food according to FC 13.1.5.1
(dietary foods for infants for special medical purposes and special formulae for infants) and FC
13.1.5.2 (dietary foods for babies and young children for special medical purposes as defined in
Directive 1999/21/EC) in infants above 16 weeks of age and young children up to 3 years and the
safety in the special subpopulation of infants below 16 weeks of age.
The process which followed involved the publication of a dedicated call for data allowing all
interested business operators to provide the requested information for completing the assessment as
pointed out above and to confirm that the additive is used in FC 13.1.5.1 and is also present in infant
formula (13.1.1) as a carryover resulting from the authorised use in Regulation (EC) No 1333/2008.
The data submitted in response to the call for data on SSOS (E 1450) comprise technical
information on impurities of the additive, formulation examples for products on the market, use levels
in relevant infant formulae, toxicity data such as a report on a 3-week dietary study on piglets, clinical
data and post-marketing surveillance reports. No adequate data were submitted by the interested
business operators which can serve as the basis to assess the safety of SSOS (E 1450) in the use
according to FC 13.1.5.1 and 13.1.5.2 for uses in food for infants above 16 weeks and young children.
SSOS (E 1450) is a starch esterified with octenylsuccinic anhydride. Specifications for SSOS have
been defined in Commission Regulation (EU) No 231/2012. Considering the data submitted in response
to the call for data, the Panel considered it feasible to amend a number of specifications. This refers to
lower existing limits for SO2, for toxic elements (heavy metals), as well as introducing new
specifications for cadmium and microbiological criteria for the food additive.
Currently, SSOS (E 1450) is approved for use in dietary foods for infants for special medical
purposes and special formulae for infants (FC 13.1.5.1) at a maximum level 20,000 mg/L (or mg/kg,
as appropriate) only in infant formulae and follow-on formulae according to Annex II to Regulation
(EC) No 1333/2008. Additionally, SSOS (E 1450) is approved for use in dietary foods for babies and
young children for special medical purposes as defined in Directive 1999/21/EC (FC 13.1.5.2) at a
maximum level of 20,000 mg/L (or mg/kg, as appropriate) and 50,000 mg/L (or mg/kg, as
appropriate; only processed cereal-based foods and baby foods). According to Annex III, Part 5 of
Regulation (EC) No 1333/2008, SSOS (E 1450) is also authorised as a food additive added in nutrients
i.e. vitamin preparations and polyunsaturated fatty acid preparations, intended to be used in foods for
infants and young children listed in point 13.1 of part E of Annex II, at carry-over levels of 100 and
1,000 mg/kg, respectively.
An in vitro digestibility study and an in vivo study addressing the absorption, distribution,
metabolism and excretion of SSOS were available from the former evaluation. Additionally, a study in
juvenile rats was described by the World Health Organization (WHO) monograph and additional studies
in humans were also available. Comparison among different species and data comparing young and
old population were not available.
Regarding the microbiome, in infants, it is known that the microbiome depends on different factors
including the mode of delivery, the feeding, the age, diet, host genetics, antibiotic usage and the birth
environment of the infants, e.g. neonatal intensive care unit (NICU). According to the reviewed
literature, more data are required for a better understanding of the interaction between the factors
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and what is necessary to maintain intestinal homoeostasis in terms of microbiome in the different
population groups. The Panel noted that changes in the composition of the gut microbiota without
measuring a specific health outcome are difficult to interpret.
In the animal studies evaluated by the Panel on Food Additives and Nutrient Sources added to Food
(ANS), no indication of significant toxic effects of SSOS was observed. However, the FAF
Panel considered that the 8-week study in weanling rats and the 90-day rat study were not
appropriate for the evaluation of SSOS as a food additive in food for infants below 16 weeks of age. In
the study in pups of Beagle dogs up to 10,000 mg SSOS/kg body weight (bw) per day for 6 weeks
effects on body weight and food consumption were not described. The full study report was not
available to the Panel, and therefore, reference point could not be derived from this study.
The results of the post-natal study in piglets were considered by the FAF Panel as the most suitable
animal data for the evaluation of SSOS as food additive in food for infants below 16 weeks of age.
However, due to the absence of effects in female animals and a lack of a dose-response in the effect
on body weights of male piglets, the Panel could not identify a reference point for the hazard
characterisation of SSOS based on the data from this study.
Further to the call for data, six clinical trials conducted in infants below 16 weeks of age were
submitted by interested business operators. Two reviewers evaluated independently the six studies
concerning the risk of bias applying an assessment tool modified from the OHAT RoB tool. Five of the
studies were allocated to tier 3. Concerning the outcome of the assessment of RoB of the clinical
studies, it is general agreement that studies allocated to tier 3 can only be used as supportive
evidence. One study was allocated to tier 2 (moderate risk of bias).
Dietary exposure to SSOS (E 1450) from its use as a food additive was assessed based on (1)
maximum permitted levels (MPLs) set out in the EU legislation (defined as the regulatory maximum
level exposure assessment scenario) and (2) the reported use levels (defined as the refined exposure
assessment scenario), (3) the levels in the formulas given as interventions in the clinical trials
considered in this assessment. Both scenarios (1) and (2) are based on the recommended
consumption levels from the Scientific Committee Guidance which recommends values of 200 and 260
mL formula/kg bw per day as conservative mean and high level consumption values for 14–27 days
old infants.
For infants below 16 weeks of age consuming foods for special medical purposes (FSMP) (FC
13.1.5.1), mean exposure in the regulatory maximum level exposure assessment scenario was
estimated at 4,000 mg/kg bw per day while at the high level was estimated at 5,200 mg/kg bw per
day. As the maximum level provided by industry was equal to the MPL of 20,000 mg/kg, exposure
estimates are the same for the refined scenario based on maximum levels of use provided by the
interested business operators. For the scenario using the mean of the reported use levels from
industry, exposure estimates were of 1,676 mg/kg bw per day at the mean and 2,179 mg/kg bw per
day at the high level.
The lowest levels of exposure to SSOS (E 1450) estimated for the clinical trials were
the highest level of exposure was about 2,700 mg/kg bw per day.
For infants below 16 weeks of age consuming infant formulae which could contain SSOS (E 1450)
from carry-over (FC 13.1.1), in the regulatory maximum level exposure assessment scenario, mean
exposure was estimated at 220 mg/kg bw per day while at the high level was estimated at 286 mg/kg
bw per day. For the scenario using the maximum level provided by industry, mean exposure was
estimated at 77 mg/kg bw per day while at the high level was estimated at 100 mg/kg bw per day.
The scenario using the mean of the reported use levels from industry, mean exposure was estimated
12 mg/kg bw per day at the mean and 16 mg/kg bw per day at the high level.
When considering the available information to set a reference point, studies in healthy infants,
would be the preferred data source. However, most of them (five of the six studies provided) had low
internal validity, reflected in the high risk of bias (tier 3). The study with a moderate risk of bias (tier
2) had very low content of SSOS in the formulae used in both study arms of . In
addition, in all the studies, the composition of the control formula, used without SSOS (E 1450),
differed from the composition of the experimental formula with SSOS (E 1450). The Panel explored the
possibility to compare the studies concerning growth with non-randomised comparisons (i.e.
comparisons to historical controls, such as comparisons to growth reference charts the data of which
are of observational nature), but considered that the available data on these growth reference charts
were not sufficiently informative for the European population. Hence, the Panel concluded that a
reference point could not be derived from the clinical studies. The Panel considered whether the
results from the piglet study could be used for identifying a reference point but had to note that the
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uncertainty surrounding the results precludes deriving a reference point from this study. On the other
hand, both data sources did not clearly indicate an adverse effect due to SSOS. Given the available
data, the FAF Panel reiterated the conclusion of the ANS Panel that there was no need for a numerical
acceptable daily intake (ADI) and considered that for exposure to SSOS of infants below 16 weeks,
there is no indication for a concern when within the range reported in the clinical studies (up to 2,725
mg/kg bw per day). When extrapolating the conclusion above to the safety assessment of the food
additive when used in FCs 13.1.5.1 and 13.1.5.2 in food for infants above 16 weeks of age and young
children, the Panel considered that for exposure to SSOS for infants above 16 weeks and young
children, there is no indication for a concern when within the range reported in the clinical studies (up
to 2,725 mg/kg bw per day). The Panel noted that at the reported use levels, the estimates of
exposure could exceed the higher end of the exposure in the clinical trials.
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1. Introduction
The present opinion deals with:
• the risk assessment of starch sodium octenyl succinate (E 1450) in food for infants below 16
weeks of age in the food category (FC) 13.1.5.1 (‘Dietary foods for special medical purposes
and special formulae for infants’), and referring to carry over from indirect use in nutrients
(Annex II and section B of part 5 of Annex III to the Regulation (EC) No 1333/20081 on food
additives).
• the follow-up on issues that have been expressed in the conclusions and recommendations of
the Scientific Opinion on the re-evaluation of starch sodium octenyl succinate (E 1450) as a
food additive (EFSA ANS Panel, 2017) including the risk assessment of starch sodium octenyl
succinate (E 1450) for the use as food additive in food according to FC 13.1.5.1 and FC
13.1.5.2 (dietary foods for babies and young children for special medical purposes as defined
in Directive 1999/21/EC) in infants above 16 weeks of age and young children up to 3 years.
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background
The composition of food intended for infants and young children, as defined by Regulation (EU) No
609/20132, is regulated at EU level and such rules include requirements concerning the use of
substances as food additives.
The use of food additives is regulated by Regulation (EC) No 1333/2008 on food additives. Only
food additives that are included in the Union list, in particular in Annex II and III to that Regulation,
may be placed on the market and used in food under the conditions of use specified therein.
In accordance with Regulation (EU) No 257/20103, EFSA is currently re-evaluating the safety of
food additives already permitted in the Union before 20 January 2009 and issuing scientific opinions on
their safety when used in food as per Annexes II and III to Regulation (EC) No 1333/2008. However,
the risk assessment approach followed until now has not covered the use of food additives in food for
infants below 12 weeks of age. Consequently, EFSA published several scientific opinions on the re-
evaluation of the safety of food additives permitted in food category 13.1 but not addressing their use
in food for infants below 12 weeks of age.
In addition, in these opinions EFSA identified some concerns, namely 1) Data gaps that have
triggered recommendations in the (to be) published scientific opinions, and/or; 2) Data gaps that have
increased uncertainties linked to the risk assessment and/or which prevented the Panel from
concluding on some aspects of it.
On 31 May 2017, EFSA published a guidance document (EFSA Scientific Committee, 2017a,b) on
the risk assessment of substances present in food intended for infants below 16 weeks of age, thus
enabling EFSA to assess the safety of food additive used in food for infants below 12 weeks of age.4
Now EFSA is expected to launch dedicated calls for data to be able to perform such risk assessments.
The EC considers more effective that EFSA, in the context of these dedicated calls for data, also
addresses all the issues and data gaps already identified in the relevant (to be) published scientific
opinions on the re-evaluation of the safety of food additives permitted in food category 13.1.
In accordance with the current EC approach for the follow-up of EFSA’s scientific opinions on the
re-evaluation of the safety of permitted food additives for which some concerns have been identified, a
specific call for data would be published by the EC on DG SANTE’s website5 on food additives and
additional (missing) information would then be provided by interested business operators to the EC.
1 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives (Text
with EEA relevance). OJ L 354, 31.12.2008, p. 16–33.
2 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive
92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the
European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009. OJ L 181,
29.6.2013, p. 35–56.
3 Commission Regulation (EU) No 257/2010 of 25 March 2010 setting up a programme for the re-evaluation of approved food
additives in accordance with Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives.
OJ L 80, 26.3.2010, p. 19–27.
4 See Section 1.1.3.
5 https://ec.europa.eu/food/safety/food_improvement_agents/additives/re-evaluation_en
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However, for those scientific opinions on the re-evaluation of the safety of permitted food additives
in food category 13.1 for which the risk assessment does not address their uses in food for infants
below 12 weeks of age and for which some concerns have been identified by EFSA, the EC considers
that for the sake of efficiency it would be appropriate to streamline the approach as described above.
Therefore, the EC requests EFSA to address all the issues and data gaps already identified in the
relevant (to be) published scientific opinions of those food additives (or groups of additives that can be
addressed simultaneously) as part of the upcoming work on the safety assessment of food additives
uses in food for infants below 12 weeks of age.
This follow-up aims at completing the re-evaluation of the food additives in question for all food
categories, and includes calls for data covering the actual use and usage levels of food additives in
food for both infants below 12 or 16 weeks of age as well as for older infants, young children and
other groups of the population for which EFSA has already finalised its assessment.
The future evaluations of EFSA should systematically address the safety of use of food additives for
all age groups, including the infants below 12 or 16 weeks of age.
1.1.2. Terms of Reference
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20026, and as part of EFSA’s work in
completing its risk assessments concerning the use of food additives in food for infants below 12
weeks of age, covered by the re-evaluation programme and its terms of reference, the European
Commission requests the European Food Safety Authority to address all the data gaps specified in the
recommendations made in its scientific opinions on the re-evaluation of the safety of food additives
permitted in food category 13.1 (food for infants and young children) of annex II to Regulation (EC)
No 1333/2008.
1.1.3. Interpretation of Terms of Reference
The Panel noted that the use of ingredients for infant formula and follow-on formula is regulated by
Commission Delegated Regulation (EU) 2016/127 of 25 September 2015 on infant formulae and
follow-on formulae,7 clearly stating that ‘The use of ingredients containing gluten shall be prohibited8’.
Therefore, the food additive starch sodium octenyl succinate (E 1450) in infant formulae and
follow-on formulae should not contain gluten.
Before the publication of the EFSA Scientific Committee Guidance on the risk assessment of
substances present in food intended for infants below 16 weeks of age (EFSA Scientific Committee,
2017a,b), EFSA has taken 12 weeks as a cut off age for the applicability of the safety assessment.
However, according to EFSA Scientific Committee (2017a,b), the assessment will include infants up to
16 weeks of age because they are exposed to formula feeding until this age as the only source of food
since complementary feeding is not supposed to be introduced before this age (see EFSA Scientific
Committee, 2017a,b).
1.2. Previous evaluations of starch sodium octenyl succinate (E 1450)
for use in foods for infants
The safety of starch sodium octenyl succinate (E 1450), abbreviated as SSOS,9 for use as an
emulsifier in infant formula and in formula for special medical purposes (FSMP) intended for use in
infants was evaluated by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) at its 79th
meeting in 2014 (JECFA, 2015).
According to the JECFA evaluation (JECFA, 2015): ‘The fates of OSA-modified starch10 and the
hydrolysed product OSA (octenyl succinic acid) are similar in rats, dogs and human infants with respect
6 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
7 Commission Delegated Regulation (EU) 2016/127 supplementing Regulation (EU) No 609/2013 of the European Parliament and
of the Council as regards the specific compositional and information requirements for infant formula and follow-on formula and
as regards requirements on information relating to infant and young child feeding. OJ: JOL_2016_025_R_0001, p. 1–29.
8 The same statement is mentioned in the Commission delegated Regulation of 25 September 2015 that will apply for infant
and follow-on formulae from 22 February 2020, except for formulae manufactured from protein hydrolysates (applicable from
22 February 2021).
9 Octenyl succinic acid (OSA)-modified starch, name used by JECFA (2014, 2015).
10 Editorial addition.
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to enzyme hydrolysis in the digestive tract, followed by absorption, metabolism and elimination, with
the only difference being the amount of OSA excreted unchanged in the urine. The clinical data
indicate that infants are able to metabolise SSOS to a number of metabolites, including propane-1,2-3-
tricarboxylic acid. While the degree of metabolism may differ among species, in general, the same
metabolites are produced.’
Exposure estimates calculated on the basis of the energy intakes at the maximum proposed use level
of 20 g/L formula (energy density of 67 kcal/100 mL) resulted in median and high levels of 3.7 g/kg body
weight (bw) per day and 4.4 g/kg bw per day, respectively. The highest reported 95th percentile energy
intakes were for infants aged 14–27 days, the median referred instead to infants aged 0–6 months
(JECFA, 2015).
Two toxicity studies in neonatal animals were considered by JECFA in this assessment, one conducted
in beagle pups and another in neonatal piglets. The latter was considered to be more relevant for the
safety assessment because of the similarity between the digestive system of neonatal swine and human
infants. From the study in neonatal piglets, a no-observed-adverse-effect level (NOAEL) was identified at
10,000 mg/kg bw per day, corresponding to the highest dose tested (JECFA, 2015).
Data from a 90-day oral toxicity study in rats were also reviewed, showing no treatment-related
adverse effects at doses up to 37,000 mg/kg bw per day. Data from post-marketing monitoring and
clinical studies in infants were also considered for the evaluation. Based on the above, in its evaluation,
JECFA concluded that: ‘the consumption of OSA-modified starch8 in infant formula or formula for special
medical purposes intended for infants is not of concern at use levels up to 20 g/L’ (JECFA, 2015).
1.3. Summary of the previous EFSA re-evaluation of SSOS (E 1450) for
uses in foods for all population groups except for infants below 12
weeks of age
Under the frame of Regulation (EC) No 257/2010, the EFSA Panel on Food Additives and Nutrient
Sources added to Food (ANS) has re-evaluated the safety of SSOS (E 1450) when used as a food
additive (EFSA ANS Panel, 2017).
The scientific opinion on the safety of SSOS (E 1450) also encompassed the assessment of other
starches used as food additives, namely: oxidised starch (E 1404), monostarch phosphate (E 1410),
distarch phosphate (E 1412), phosphated distarch phosphate (E 1413), acetylated distarch phosphate
(E 1414), acetylated starch (E 1420), acetylated distarch adipate (E 1422), hydroxypropyl starch (E
1440), hydroxypropyl distarch phosphate (E 1442), acetylated oxidised starch (E 1451) and starch
aluminium octenyl succinate (E 1452). The assessment performed by the ANS Panel was, however,
incomplete with respect to the safety of SSOS (E 1450) for use in food for infants below 16 weeks of age.
In its scientific opinion, the ANS Panel reviewed available technical, biological and toxicological data
on the above-mentioned modified starches used as food additives, including data on SSOS (E 1450). A
combined dietary exposure estimate was calculated in the general population for the modified starches
E 1404, E 1410, E 1412, E 1413, E 1414, E 1420, E 1422, E 1440, E 1442, E 1450 and E 1451
resulting in maximum intake levels of approximately 3 g/kg bw per day in toddlers at the 95th
percentile in the brand-loyal consumer scenario. The ANS Panel concluded that there was no safety
concern for the use of modified starches as food additives at the reported uses and use levels and that
there was no need for a numerical ADI for the general population (EFSA ANS Panel, 2017).
Based on the data reviewed, the ANS Panel had concluded that in humans modified starches, such
as SSOS (E 1450), would not be absorbed intact but would be significantly hydrolysed by intestinal
enzymes and then fermented by intestinal microbiota. In the specific case of SSOS (E 1450), the ANS
Panel had concluded that the octenyl succinate moiety of the modified starch would either be
metabolised to tricarboxylic acid or excreted unchanged (EFSA ANS Panel, 2017).
From the toxicological data set reviewed, which was considered to adequately cover all relevant
toxicity endpoints, no treatment-related effects of modified starches were observed even after long-
term treatment at high levels (up to 17,000 mg/kg bw per day) (EFSA ANS Panel, 2017).
Although no genotoxicity data on the modified starches were available for the re-evaluation, the
Panel had considered the lack of structural alerts based on the use of an in silico predictive tool as
sufficient evidence to rule out possible genotoxic concerns (EFSA ANS Panel, 2017).
However, with respect to the uses of SSOS (E 1450) in the food categories ‘13.1.5.1 Dietary foods
for special medical purposes and special formulae for infants’ and ‘13.1.5.2 Dietary foods for babies
and young children for special medical purposes as defined by Commission Directive 1999/22/EC’ at
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the maximum use levels of 20,000 or 50,000 mg/kg, respectively, the ANS Panel had concluded that
the available data did not allow for an adequate assessment of the safety.
In its scientific opinion, the ANS Panel, cited the JECFA evaluation (JECFA, 2015) reporting no
effects on body weight and food intake in male and female neonatal pigs exposed to 10,000 mg/kg bw
per day of SSOS (E 1450) in formula for 21 days. Furthermore, it was noted that in the JECFA (2015)
evaluation SSOS (E 1450), up to a single dose of 25,000 mg/person was reported to be well tolerated
by fasting healthy adults, but gastrointestinal symptoms were reported in infants with hypoallergenic
formula containing 2% of SSOS (about 24,000 mg/person). The ANS Panel was also concerned with
the possibility that infants and young children consuming foods belonging to the two food categories
13.1.5.1 and 13.1.5.2 may show a higher susceptibility to the gastrointestinal effects of modified
starches than their healthy counterparts due to their underlying medical condition. The available
information on the clinical studies in infants was considered too limited by the ANS Panel also because
the results referred to the feeding of formula products containing SSOS in concentrations lower than
the currently authorised maximum level. The level of exposure in populations consuming foods for
special medical purposes and special formulae was estimated to be up to 5,286 mg/kg bw per day for
infants at the 95th percentile (EFSA ANS Panel, 2017). The ANS Panel had therefore recommended the
evaluation of additional data for completing the assessment for these uses.
From the former ANS opinion (EFSA ANS Panel, 2017) which dealt with the safety of SSOS (E 1450)
in the general population, several issues required follow-up and additional data that were requested in
a dedicated call for data11 (see also Appendix B).
2. Data and methodologies
2.1. Data
EFSA launched a public call for data11 to collect relevant information from interested business
operators.
The Panel based its assessment on the information submitted to EFSA following the public call for
data, the information from previous evaluations and additional available literature up to 22 June 2020.
The Mintel’s Global New Products Database (GNPD) is an online database which monitors new
introductions of packaged goods in the market worldwide. It contains information of over 3 million
food and beverage products of which more than 1,100,000 are or have been available on the
European food market. Mintel started covering EU’s food markets in 1996, currently having 24 out of
its 27 member countries, and Norway and UK presented in the Mintel GNPD.12 The Mintel’s GNPD
database was consulted to verify the use of the food additive SSOS (E 1450) in food products.
2.2. Methodologies
This opinion was formulated following the principles described in the EFSA Guidance on
transparency with regard to scientific aspects of risk assessment (EFSA Scientific Committee, 2009)
and following the relevant existing guidance documents from the EFSA Scientific Committee including
the EFSA Guidance of the Scientific Committee on the risk assessment of substances present in food
intended for infants below 16 weeks of age (EFSA Scientific Committee, 2017a).
In order to conclude on the safety of SSOS (E 1450) for all population groups and to address the
data gaps identified during the re-evaluation, the FAF Panel assessed the information provided:
• for the follow-up on issues that have been raised in the conclusions and recommendations of
the Scientific Opinion on the re-evaluation of SSOS (E 1450) as a food additive including the
risk assessment of starch sodium octenyl succinate (E 1450) for the use as food additive in
food according to FC 13.1.5.1 and FC 13.1.5.2 (dietary foods for babies and young children for
special medical purposes as defined in Directive 1999/21/EC) in infants above 16 weeks of age
and young children up to 3 years (EFSA ANS Panel, 2017); and
• for the risk assessment of SSOS (E 1450) in food for infants below 16 weeks of age in the FC
13.1.5.1 (Dietary foods for infants for special medical purposes and special formulae for
11 Call for technical and toxicological data on starch sodium octenyl succinate (E 1450) for uses as a food additive in foods for all
population groups including infants below 16 weeks of age. Available from: http://www.efsa.europa.eu/en/consultations/call/
180718-4.
12 Missing Cyprus, Luxembourg and Malta.
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infants), and referring to carry over from indirect use in nutrients (Annex II and section B of
part 5 of Annex III to the Regulation (EC) No 1333/2008 on food additives).
When in animal studies, the test substance was administered in the feed or in drinking water, but
doses were not explicitly reported by the authors as mg/kg bw per day based on actual feed or water
consumption, the daily intake is calculated by the Panel using the relevant default values. In case of
rodents, the values as indicated in the EFSA Scientific Committee Guidance document (EFSA Scientific
Committee, 2012) are applied. In the case of other animal species, the default values by JECFA (2000)
are used. In these cases, the dose was expressed as ‘equivalent to mg/kg bw per day’. When in
human studies in adults (aged above 18 years) the dose of the test substance administered was
reported in mg/person per day, the dose in mg/kg bw per day was calculated by the Panel using a
body weight of 70 kg as default for the adult population as described in the EFSA Scientific Committee
Guidance document (EFSA Scientific Committee, 2012).
The animal post-natal study and the human clinical trials were assessed by two reviewers
(members of the Working Group) applying an assessment tool modified from the OHAT RoB tool (NTP-
OHAT, 2015, 2019). The elements considered for the appraisal are described in Appendices C and D of
this opinion, as well as the decision rule for assigning the studies to tiers of reliability.
Dietary exposure to SSOS (E 1450) from its use as a food additive in foods for infants below 16
weeks of age was estimated combining the mean and highest consumption figures reported for the
period of 14–27 days of life which corresponds to values of 200 and 260 mL/kg bw per day,
respectively, with the maximum levels according to Annex II and Annex III, Part 5 Section B to
Regulation (EC) No 1333/2008 and/or reported use levels submitted to EFSA following a call for data.
Different scenarios were used to calculate exposure (see Section 3.3.1). Uncertainties on the exposure
assessment were identified and discussed.
As SSOS (E 1450) is also authorised in the food category 13.1.5.2, an exposure assessment
considering FC 13.1.5.1 and FC 13.1.5.2 was performed to estimate the exposure of infants (above 16
weeks) and toddlers who may eat and drink these foods for special medical purposes (FSMP).
The consumption of these foods is not reported in the EFSA Comprehensive database. To consider
potential exposure to SSOS (E 1450) via these foods, the Panel assumes that the amount of FSMP
consumed by infants and toddlers resembles that of comparable foods in infants and toddlers from the
general population. Thus, the consumption of FSMP categorised as FC 13.1.5 was assumed equal to
that of formulae and food products categorised as FCs 13.1.1, 13.1.2, 13.1.3 and 13.1.4.
3. Assessment
3.1. Technical data
3.1.1. Identity of the substance
According to Commission Regulation (EU) No 231/201213, the food additive E 1450 is named as
starch sodium octenyl succinate. A generic representation of the structure of starches is shown in
Figure 1. To make the food additive with the desired functionality, starch is chemically modified by
esterification of some of its hydroxyl groups with octenylsuccinic anhydride. This reaction is depicted in
Figure 2, where in this example sodium hydroxide is used in the reaction to provide the sodium salt.
13 Commission Regulation (EU) No 231/2012 of 9 March 2012 laying down specifications for food additives listed in Annexes II
and III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council. OJ L 83, 22.3.2012, p. 1–295.
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3.1.2. Specifications
The specifications for SSOS (E 1450) as defined in the Commission Regulation (EU) No 231/2012
and tentative specifications as proposed by JECFA (2018) are listed in Table 1. At its 79th meeting,
JECFA recommended the separation of the combined specification for the modified starches into 16
separate specifications (JECFA, 2014). As a first step, 16 stand-alone specification monographs were
prepared at the 82nd JECFA meeting and published in FAO JECFA Monographs 19 (JECFA 2016a,
2017). For SSOS (E 1450), the resulting individual specification monograph was incomplete and
therefore got the tentative status due to pending information (JECFA, 2016b). At the 86th JECFA
meeting (JECFA, 2018), this concept was refined: all modified starches were included in a ‘modular
monograph’ consisting of ‘general specifications’ that contains common specifications to all modified
starches and eight ‘annexes’ with specifications applicable to each individual modified starch based on
the chemical treatment(s) that native starches received. The status of these specifications is tentative.
Furthermore, JECFA requested suitable microbiological acceptance criteria and supporting data for all
modified starches (JECFA 2016a).
Figure 1: Structural formula of starch as reproduced in EFSA ANS Panel (2017)
Figure 2: Process for derivatisation of starch to generate SSOS (Image from RSC14)
14 Taken from: https://pubs.rsc.org/image/article/2015/ra/c5ra10849g/c5ra10849g-s3_hi-res.gif. Accessed on 29 August 2019.
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Table 1: Specifications for SSOS (E 1450) according to Commission Regulation (EU) No 231/2012
and for modified starches, including INS 1450, tentatively proposed by JECFA (2018)
Commission
Regulation (EU)
No 231/2012
JECFA, tentative (2018)
Definition Starch sodium octenyl
succinate is starch
esterified with
octenylsuccinic anhydride
General for modified starches: Starch consists mainly of
amylose and amylopectin. Amylose is a linear molecule of
a-D-glucopyranosyl units linked by (1-4)-a-linkages.
Amylopectin is a highly branched polymer of a-D-
glucopyranosyl units linked by (1-4)-a-linkages and by (1-6)-
a-linkages that constitute the branch points. Each glucose unit
possesses a maximum of three hydroxyls that can undergo
chemical substitution
Native starches can be physically (pre-gelatinised starches)
and/or chemically modified for improved functionality. The
most common sources of native starch used in these
modifications are various roots, tubers, cereals and legumes.
Modified starches are used in applications requiring special
properties not attainable by native starches
Chemical modifications of native starches are often
performed, in an aqueous suspension under controlled
conditions of pH, time and temperature, unless otherwise
indicated in the description of the respective annex. After
sufficient reaction time, the modified starch is recovered by
filtration or centrifugation, washed with water, dried and
packaged. The relevant modification reactions can be,
separately or in combination, fragmentations (hydrolysis,
oxidation, enzymatic), bleaching, oxidation, esterification,
etherification or phosphorylation of one or more of the
hydroxyl groups of the a-D-glucopyranosyl units or
crosslinking using polyfunctional agents
Treatment – Octenylsuccinic anhydride can be used for the esterification
and either sodium hydroxide or sodium carbonate as a pH
buffer for neutralisation
Synonym SSOS
CAS Numbers Starch sodium octenyl succinate
66829-29-6 (modified starch)
52906-93-1 (modified starch)
125109-81-1 (modified amylopectin)
Description White or nearly white
powder or granules or (if
pregelatinised) flakes,
amorphous powder or
coarse particles
White or nearly white powder or granules or (if
pregelatinised) flakes, or amorphous powder or coarse
particles
Identification
Solubility – Insoluble in cold water (if not pregelatinised); forming typical
colloidal solutions with viscous properties in hot water;
insoluble in ethanol
Microscopic
observation
Passes test (if not
pregelatinised)
Passes test
Iodine staining Passes test (dark blue to
light red colour)
Passes test
Copper reduction – Passes test
Ester groups – Passes test
Purity
pH 3.0-9.0
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3.1.2.1. Technical data from commercial samples of the food additive
Analytical data from 27 batches of commercial samples of SSOS (E 1450) have been provided by
one of the interested parties in response to the call for data (Documentation provided to EFSA n. 1).
Based on the analytical data submitted along with the performance of the analytical methods used,
the following purity criteria are proposed by Starch Europe:
Commission
Regulation (EU)
No 231/2012
JECFA, tentative (2018)
Loss on drying Not more than 15.0% for
cereal starch
Not more than 21.0% for
potato starch
Not more than 18.0% for
other starches
Cereal starch: not more than 15.0%
Potato starch: not more than 21.0%
Other starches: not more than 18.0%
Conditions: 120°, 4 h, vacuum not exceeding 100 mmHg
Octenylsuccinyl
groups
Not more than 3% (on an
anhydrous basis)
Not more than 3% on the dried basis
Octenylsuccinic
acid residue
Not more than 0.3% (on
an anhydrous basis)
Not more than 0.3% on the dried basis
Carboxyl groups – Not more than 0.1% on the dried basis
Sulfur dioxide Not more than 50 mg/kg
for modified cereal
starches (on an
anhydrous basis)
Not more than 10 mg/kg
for other modified
starches, unless
otherwise specified (on
an anhydrous basis)
Not more than 50 mg/kg on the dried basis for modified
cereal starches
Not more than 10 mg/kg on the dried basis for other modified
starches
Arsenic Not more than 1 mg/kg –
Lead Not more than 2 mg/kg
(on an anhydrous basis)
Not more than 0.2 mg/kg on the dried basis
Not more than 0.1 mg/kg on the dried basis for Starch
sodium octenylsuccinate (INS 1450) for use in infant formula
and formula for special medical purposes intended for infants
Mercury Not more than 0.1 mg/kg –
Manganese – Not more than 50 mg/kg on the dried basis
Microbiological criteria
Aerobic plate count Not more than 1,000 CFU/g
Yeasts and moulds Not more than 1,000 CFU/g
Total coliforms Not more than 10 CFU/g
CFU: colony-forming units.
Table 2: Proposed purity criteria by Starch Europe (Documentation provided to EFSA n.1) for SSOS
(E 1450) for uses in food for infants below 16 weeks of age
Limit proposed by Starch Europe
(only for uses in food for infants
below 16 weeks of age):
Method(s)
Arsenic Not more than 0.05 mg/kg NMKL No.161, 1998, mod 13805:2014
Two further, in-house, methods described, using
open- or closed vessel acid digestion of samples
followed by ICP-MS determination of the elements
Cadmium Not more than 0.01 mg/kg NMKL No.161, 1998, mod 13805:2014
Two further, in-house, methods described, using
open- or closed vessel acid digestion of samples
followed by ICP-MS determination of the elements
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No analytical data and no proposal for specifications for use in food for other population groups
than infants below the age of 16 weeks were provided as requested in part A.1 of the call for data11
(clarification letter by Starch Europe dated 29 October 2019).
Eight commercial samples of SSOS (E 1450) sold to baby food industry were tested for Cronobacter
(Enterobacter) sakazakii using the method ISO/TS 22964. All tested samples were negative
(Documentation provided to EFSA n.1).
The proposed revisions of the EU specifications are presented in Section 3.5.
3.1.2.2. Analytical data on toxic elements in final infant formulae
As part of the EFSA call for data,11 information on the concentrations of toxic elements for which
legal limits are not in place in the final products – i.e. infant formulas made using SSOS (E 1450) was
requested. Only limited information was provided, covering just a few samples and for an incomplete
Limit proposed by Starch Europe
(only for uses in food for infants
below 16 weeks of age):
Method(s)
Lead Not more than 0.03 mg/kg NMKL No.161, 1998, mod 13805:2014
Two further, in-house, methods described, using
open or closed vessel acid digestion of samples
followed by ICP-MS determination of the elements
Mercury Not more than 0.05 mg/kg SS-EN 16277:2012
Two further, in-house, methods described, using
open or closed vessel acid digestion of samples
followed by ICP-MS determination of the elements
Lowest technologically achievable
levels proposed by Starch Europe
Method(s)
SO2 10 mg/kg Three methods reported:
SS-EN-1988-2
NE EN 1185
990.28 AOAC (16th Edition, Chapter 47)
Octenylsuccinic
acid residue
0.3% Ranging from 0.06% to 0.3%
Measured in 13 samples according to JECFA
specifications for modified starches
Microbiological criteria
Salmonella spp. Negative in 25 g (3 samples; method: Rapid Salmonella Short prot)
Negative in 375 g (5 samples: US FDA Bacteriological Analytical Manual (BAM) Chapter 5)
Other 13 negative samples, method unclear
E. coli Negative in 10 g (3 samples; method: ISO 7251)
Negative in 10 g (5 samples; method: Modified USP 62)
Other 13 negative samples, method unclear
Aerobic plate
count
< 100 CFU/g (3 samples; method: NMKL 86)
< 10 CFU/g (8 samples; ISO 4833)
< 10 CFU/g (5 samples; Modified USP 61)
Other samples tested, method unclear
Yeast < 100 CFU/g (3 samples; method: 3M Petrifilm Rapid)
< 5 CFU/g (2 samples; method: NF v08-059)
< 10 CFU/g (3 samples; method: NF v08-059)
< 10 CFU/g (5 samples; method: Modified USP 61)
Other samples tested, method unclear
ICP-MS: Inductively coupled plasma mass spectrometry; CFU: colony-forming unit.
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set of elements of potential concern (Documentation provided to EFSA by a Specialised Nutrition Europe
(SNE) member). Nonetheless, considering the recommendation that specifications for the content of
certain toxic elements should be tightened (see above) then further analytical data for the final infant
formulae was not requested because if these specifications were applied, the concentrations of toxic
elements in the final products would not raise concern.
3.1.3. Stability of the substance, and reaction and fate in food
SSOS (E 1450) is produced through the esterification of a food starch with octenylsuccinic
anhydride. According to the European Commission specifications (Table 1), the content of
octenylsuccinyl groups (i.e. esterified with the starch hydroxyl groups) should not exceed 3% w/w and
the unreacted residue of octenylsuccinic acid (i.e. free, unbound) should not exceed 0.3% w/w.
Concerning the starch backbone, starch and OSA starches are stable powders with a long shelf-life.
There is no reason to believe that when mixed with other non-active powder ingredients and used as
intended, this would change.
Considering the possibility of hydrolysis, the additive is stable in infant formulae products. Under
normal conditions of use for both powdered and liquid infant formulae products, it would not be
expected that more than a minor fraction of the octenylsuccinyl group hydrolyse. This is supported by
a study (Johns et al., 2014) in which the dissociation of octenylsuccinic acid from SSOS (E 1450)
during the production of a hydrolysed protein-based nutritional product was evaluated. Even under
these severe manufacturing conditions (compared to normal use conditions for this additive), there
was only a minor (~ 2%) conversion of the total amount of octenylsuccinic acid from the starch-bound
form to the free form (Documentation provided to EFSA n. 2). Since the additive may already contain
about 10% free OSA (e.g. at the limit values, 0.3 free vs. 3% w/w bound, see above), such small
further release is not considered to be significant.
Considering other potential reactions of the OSA group, it contains a C=C double bond at carbons
C6 and C7 of the octyl chain (see Figure 2). This double bond is isolated insofar as it is not in
conjugation with and cannot foreseeably become conjugated with (and thereby activated by) another
site of unsaturation such as a carbonyl or other alkene bond. So, no reactivity at that site is foreseen
when the additive is used in infant food products.
3.2. Authorised uses and use levels
Maximum levels of SSOS (E 1450) in foods for infants below 16 weeks of age have been defined in
Annex II and III to Regulation (EC) No 1333/2008 on food additives, as amended. In this document,
these levels are named maximum permitted levels (MPLs).
Currently, SSOS (E 1450) is approved for use in dietary foods for infants for special medical
purposes and special formulae for infants (FC 13.1.5.1) at a maximum level 20,000 mg/L (or mg/kg,
as appropriate) only in infant formulae and follow-on formulae according to Annex II to Regulation
(EC) No 1333/2008. Additionally, SSOS (E 1450) is approved for use in dietary foods for babies and
young children for special medical purposes as defined in Directive 1999/21/EC at a maximum level of
20,000 mg/L (or mg/kg, as appropriate) and 50,000 mg/L (or mg/kg, as appropriate; only processed
cereal-based foods and baby foods), see Table 3.
According to Annex III, Part 5 of Regulation (EC) No 1333/2008, SSOS (E 1450) is also authorised
as a food additive added in nutrients i.e. vitamin preparations and polyunsaturated fatty acid
preparations, intended to be used in foods for infants and young children listed in point 13.1 of part E
of Annex II, at carry-over levels of 100 and 1,000 mg/kg, respectively (see Table 3).
Table 3: MPLs of SSOS (E 1450) in foods for infants below 16 weeks of age according to the Annex II
and Annex III to Regulation (EC) No 1333/2008
Food
category
number
Food category name E-number Restrictions/exception
MPL (mg/L or
mg/kg as
appropriate)
13.1.5.1(a) Dietary foods for infants for
special medical purposes and
special formulae for infants
E 1450 Only in infant formulae and
follow-on formulae
20,000
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3.3. Exposure data
Some food additives are authorised in the EU for infant formulae as defined by Commission
Delegated Regulation (EU) 2016/127/EC) (FC 13.1.1) and in ‘dietary foods for infants for special
medical purposes and special formulae for infants’ (FC 13.1.5.1) and in ‘dietary foods for babies and
young children for special medical purposes as defined in Directive 1999/21/EC’ (FC 13.1.5.2) at a
specific MPL. However, a food additive may be used at a lower level than the MPL. Therefore, actual
use levels are required for performing a more realistic exposure assessment.
In the framework of Regulation (EC) No 1333/2008 on food additives and of Commission
Regulation (EU) No 257/2010 regarding the re-evaluation of approved food additives, EFSA issued a
public call15 for technical and toxicological data on SSOS (E 1450) for uses as a food additive in foods
for all population groups including infants below 16 weeks of age. In response to this public call,
updated information on the actual use levels of SSOS (E 1450) in foods was made available to EFSA
by industry. No analytical data on the concentration of SSOS (E 1450) in foods were made available by
the Member States.
3.3.1. Reported use levels in food category 13.1.1 as a carry-over from the
authorised use according to Annex III, Part 5, Section B
A theoretical maximum value for carry-over of 1,100 mg/kg final formulae as fed was derived using
the information in Table 6. This represents the carry-over coming from two different preparations that
could be used together in the final product. The first is the maximum authorised carry-over of 100 mg/kg
from vitamin preparations and the second is the maximum authorised carry-over of 1,000 mg/kg from
polyunsaturated fatty acids (PUFA) preparations.
Food
category
number
Food category name E-number Restrictions/exception
MPL (mg/L or
mg/kg as
appropriate)
13.1.5.2(b) Dietary foods for babies and
young children for special
medical purposes as defined in
Directive 1999/21/EC
E 1450 Only processed cereal-based
foods and baby foods
50,000
13.1.5.2(b) Dietary foods for babies and
young children for special
medical purposes as defined in
Directive 1999/21/EC
E 1450 Except processed cereal-
based foods and baby foods
20,000
Food category E-number Nutrient to which the
food additive may be
added
Annex III,
Part 5
Section B
In nutrients intended to be used
in foodstuffs for infants and
young children listed in point
13.1 of Part E of Annex II
E 1450 Vitamin preparations Carry-over 100(c)
Polyunsaturated fatty acid
preparations
Carry-over 1,000(c)
MPL: maximum permitted level.
(a): This category covers dietary foods for infants for special medical purposes and special formulae such as premature infant
formulae, hospital discharge formulae, low and very low birth weight formulae, and human breast milk fortifiers.
(b): This category covers foods specially processed or formulated and intended for the dietary management of babies and young
children, to be used under medical supervision. This includes, for example the dietary management of infants and young
children with metabolic or gastrointestinal disorders, or single or multiple food allergies or intolerances (e.g. cow’s milk
protein allergy, protein mal-absorption) and for general tube feeding. Baby foods are foodstuffs destined to children of at
least 4 months (see Article 8 of Commission Directive 2006/125).
(c): Two preparations can contain E 1450 as carry-over. In the final formula, it is in theory possible that carry-over from both
preparations are present. Therefore, for the regulatory exposure scenario, a maximum carry-over level of 1,100 mg/L or
mg/kg as appropriate was used.
15 Call for technical and toxicological data on starch sodium octenyl succinate (E 1450) for uses as a food additive in foods for all
population groups including infants below 16 weeks of age. Available online: www.efsa.europa.eu/en/consultations/call/
180718-4
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EFSA has received information on the use levels (n = 12) of SSOS (E 1450) as a food additive in
nutrients intended to be used in foodstuffs for infants and young children according to Annex III, Part
5 Section B of Regulation (EC) No 1333/2008, with respect to the carry over (FC 13.1.1) .
The levels are for:
Other data on SSOS (E 1450) were received through the general call for data batch 4 in 2016. Use
levels reported during that call are on average lower than those recently received and are not
considered in the current opinion.
Appendix A provides a summary of the use levels of E 1450 in foods as reported by industry.
3.3.2. Reported use levels in food category 13.1.5.1
Use levels were also reported for SSOS (E 1450) as a food additive in the FC 13.1.5.1 (n = 11).
These levels were provided by four companies (
).
Appendix A provides a summary of the use levels of E 1450 in foods as reported by industry.
3.3.3. Reported use levels in food category 13.1.5.2
Industry provided EFSA with three use levels of SSOS (E 1450) in FC 13.1.5.2. These levels of
SSOS (E 1450) were provided by Specialised Nutrition Europe (SNE) during the call launched in
2015.16
FC 13.1.5.2 covers all foods for babies and young children (i.e. from 4 months up to 3 years). This
includes:
– formulae
– processed cereal-based foods and baby foods
– other foods for young children (e.g. milk-based products)
The use levels received for SSOS (E 1450) for FC 13.1.5.2 only refer to formulae.
3.3.4. Summarised data extracted from the Mintel’s Global New Products
Database
The Mintel’s GNPD is an online database which monitors new introductions of packaged goods in
the market worldwide. It contains information of over 3 million food and beverage products of which
more than 1,100,000 are or have been available on the European food market. Mintel started covering
EU’s food markets in 1996, currently having 24 out of its 27 member countries, and Norway and UK
presented in the Mintel’s GNPD.12
For the purpose of this Scientific Opinion, the Mintel’s GNPD17 was used for checking the labelling
of food and beverage products and food supplements for SSOS (E 1450) within the EU’s food market
as the database contains the compulsory ingredient information on the label.
No products were found in the Mintel’s GNPD as labelled with SSOS (E 1450). The additive is
authorised for direct use (Annex II) in food for special medical purposes for infants below 16 weeks
(FC 13.1.5.1) and for babies and young children above 16 weeks of age (FC 13.1.5.2) which products
are most probably available from specialised outlets (e.g. pharmacy) not covered by the Mintel’s
GNPD. Labelling of infant formula (FC 13.1.1) with SSOS authorised according to Annex III to
Regulation N°1333/2008 (carry-over) is not mandatory.
16 Call for food additives usage level and/or concentration data in food and beverages intended for human consumption.
Published: 12 October 2015. Available online: https://www.efsa.europa.eu/en/data/call/151012
17 http://www.gnpd.com/sinatra/home/# accessed on 22/6/2020
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3.4. Exposure estimates
3.4.1. Exposure estimates for infants below 16 weeks
Exposure to SSOS (E 1450) from its uses as a food additive in formulae for infants below 16 weeks
was estimated. The scenarios are based on the recommended consumption levels from the EFSA
Scientific Committee Guidance (EFSA Scientific Committee, 2017a). This guidance ‘recommends values
of 200 and 260 mL formula18 /kg bw per day as conservative mean and high level consumption values
to be used for performing the risk assessments of substances which do not accumulate in the body
present in food intended for infants below 16 weeks of age’. These recommended consumption levels
correspond to 14- to 27-day-old infants’ consumption, at this age the consumption peaks when
expressed on a body weight basis. For the regulatory maximum level exposure assessment scenario,
the MPL for infant formulae (20,000 mg/kg for FC 13.1.5.1 and 1,100 mg/kg for FC 13.1.1) were used.
For the refined scenario, reported use levels (mean and maximum) were considered. The density of
infant formulae that is ready to feed is assumed to be 1 g/mL.
3.4.1.1. Dietary exposure to starch sodium octenyl succinate (E 1450) from FSMP
formulae
Table 4 summarises the estimated exposure to SSOS (E 1450) from its use as a food additive in FC
13.1.5.1 for infants below 16 weeks of age.
The maximum occurrence scenario was used in the assessment. The mean occurrence scenario is
reported and indicates that there are products on the market giving lower exposure levels.
3.4.1.2. Dietary exposure to starch sodium octenyl succinate (E 1450) from carry-over
into infant formulae
Table 5 summarises the estimated exposure to SSOS (E 1450) from its use as a food additive in
nutrient preparations, as carry-over in FC 13.1.1 for infants below 16 weeks of age.
Table 4: Dietary exposure to starch sodium octenyl succinate (E 1450) in foods for infants below
16 weeks of age according to the Annex II to Regulation (EC) No 1333/2008 (i.e.
considering FC 13.1.5.1) (in mg/kg bw per day)
Infants (< 16 weeks
of age)
Regulatory maximum level exposure assessment scenario (20,000 mg/kg)
• Mean consumption (200 mL/kg bw per day)
• High-level consumption (95
th percentile, 260 mL/kg bw per day)
4,000
5,200
Refined estimated exposure assessment scenario
Scenario using maximum use level reported by industry (20,000 mg/kg)
• Mean consumption (200 mL/kg bw per day)
• High-level consumption (95
th percentile, 260 mL/kg bw per day)
4,000
5,200
Scenario using mean of use levels reported by industry (8,379 mg/kg)
• Mean consumption (200 mL/kg bw per day)
• High-level consumption (95th percentile, 260 mL/kg bw per day)
1,676
2,179
bw: body weight.
18 Editorial.
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3.4.2. Exposure estimates for infants above 16 weeks of age and toddlers
consuming FSMP
As SSOS (E 1450) is also authorised in the food categories 13.1.5.1 and 13.1.5.2, an additional
exposure assessment scenario considering these two food categories was performed to estimate the
exposure of infants (above 16 weeks) and toddlers (classified as young children in Commission
Delegated Regulation (EU) 2016/127, age of 1–3 years) who may eat and drink these FSMP.
The consumption of these foods is not reported in the EFSA Comprehensive database. To consider
potential exposure to SSOS (E 1450) via these foods, the Panel assumes that the amount of FSMP
consumed by infants and toddlers resembles that of comparable foods in infants and toddlers from the
general population. Thus, the consumption of FSMP categorised as FC 13.1.5 was assumed equal to
that of formulae and food products categorised as FCs 13.1.1, 13.1.2, 13.1.3 and 13.1.4.
Use levels received for SSOS (E 1450) for FC 13.1.5.2 only refer to formulae. Therefore, use levels
reported for the FC 13.1.3 and 13.1.4 were used for calculating dietary exposure to E 1450 for infants
above 16 weeks of age and toddlers.
This scenario was estimated as follows:
– Consumers only of FSMP were assumed to be exposed to SSOS (E 1450) present at the
maximum reported use level on a daily basis via consumption of food categories 13.1.5.1
and 13.1.5.2.
– For the remaining food categories, the mean of the typical reported use levels was used.
In the refined scenario considering the whole diet, dietary exposure to SSOS (E 1450) ranged from
45 mg/kg bw per day for toddlers to 1994 mg/kg bw per day for infants above 16 weeks of age. At
the high level (95th percentile), dietary exposure to SSOS (E 1450) ranged from 250 mg/kg bw per
day for toddlers to 4069 mg/kg bw per day for infants above 16 weeks of age.
Table 5: Dietary exposure to starch sodium octenyl succinate (E 1450) due to carry-over into foods for
infants below 16 weeks of age according to the Annex III to Regulation (EC) No 1333/2008
(i.e. considering FC 13.1.1) (in mg/kg bw per day)
Infants
(< 16 weeks
of age)
Regulatory maximum carry-over scenario (1,100 mg/kg)
• Mean consumption (200 mL/kg bw per day)
• High-level consumption (95th percentile, 260 mL/kg bw per day)
220
286
Refined estimated exposure assessment scenario
Scenario using maximum carry-over level reported by industry (386 mg/kg)
• Mean consumption (200 mL/kg bw per day)
• High-level consumption (95th percentile, 260 mL/kg bw per day)
77
100
Scenario using mean of carry-over levels reported by industry (61 mg/kg)
• Mean consumption (200 mL/kg bw per day)
• High-level consumption (95th percentile, 260 mL/kg bw per day)
12
16
bw: body weight.
Table 6: Dietary exposure to starch sodium octenyl succinate (E 1450) for infants above 16 weeks
of age and toddlers, according to the Annex II to Regulation (EC) No 1333/2008
Infants (16 weeks to
11 months)
Toddlers
(12–35 months)
Refined scenario considering the whole diet (mg/kg bw per day)
• Mean
• 95th percentile
303–1,994
1,686–4,069
45–687
250–2,579
Refined scenario considering only foods from FC 13.1.5.1 and 13.1.5.2 (mg/kg bw per day)
• Mean
• 95th percentile
303–1,990
1,686–4,068
42–672
245–2,562
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For both infants and toddlers, the main contributing food categories were infant formulae as
defined by Commission Delegated Regulation (EU) 2016/127 and processed cereal-based foods and
baby foods for infants and young children as defined by Directive 2006/125/EC.
3.4.3. Uncertainty analysis
In accordance with the guidance provided in the EFSA opinion related to uncertainties in dietary
exposure assessment (EFSA, 2007), the following sources of uncertainties have been considered and
summarised in Table 7.
SSOS (E 1450) is authorised in FC 13.1.5.1 and FC 13.1.5.2 according to Annex II to Reg N°1333/2008
and in foods for infants (FC 13.1) according to Annex III.
Based on the assumption that carers of children with allergies or any other medical disorder would
be brand-loyal to an infant formula for special medical purposes (FC 13.1.5.1) that suits his medical
disorder, the refined scenario using maximum use level reported by industry (Table 4) would in general
result in an average realistic estimation of exposure for infants below 16 weeks of age.
Based on the assumption that carers would anyway be brand-loyal to an infant formula (FC 13.1.1),
the refined scenario using maximum reported use level (Table 5) would also in general result in an
average realistic estimation of exposure for infants below 16 weeks of age.
The Panel noted that information from the Mintel GNPD indicated that no FSMP products for infant
and young children were labelled with SSOS (E 1450). Considering that the maximum reported levels
were used for foods under FC 13.1.5.1 and 13.1.5.2 while mean reported use levels were used for the
rest of the diet, the Panel considered that the dietary exposure to SSOS (E 1450) would result in a
realistic estimation of the exposure to SSOS (E 1450) from its use as a food additive according to
Annex II for infants above 16 weeks of age and toddlers.
3.5. Proposed revision to existing EU Specifications for SSOS (E 1450)
The Panel considered that the maximum limits in the EU specifications for toxic elements should be
established based on actual levels measured in the food additive. Therefore, if the European
Commission decides to revise the current limits in the EU specifications to more appropriate values, the
estimations of toxic elements intake as described below could be considered.
The interested party proposed maximum limits for toxic elements (< 0.05 (As), < 0.01 (Cd), < 0.03
(Pb) and < 0.05 (Hg) mg/kg) based on the lowest technologically achievable levels which were
consistent with the analytical data, expressed as ‘less than values’ given above, provided for 27
commercial samples of the food additive (i.e. lowest achievable levels declared equal to the highest
‘less than values’ reported). Of note, the interested party declared that these analytical data and
Table 7: Qualitative evaluation of influence of uncertainties on the dietary exposure estimate
Sources of uncertainties Direction(a)
Consumption data:
– one reference point only to estimate exposure during the period of up to 16 weeks of age
– Consumption data: different methodologies/representativeness/underreporting/
misreporting/no portion size standard for subjects above 16 weeks of age
+
+/–
Methodology used to estimate high percentiles (95th) long-term (chronic) exposure based on
data from food consumption surveys covering only a few days for subjects above 16 weeks of
age
+
Correspondence of reported use levels to the food items in the EFSA Comprehensive Database:
uncertainties to which types of food the levels refer
+/–
Uncertainty in possible national differences in use levels of food categories +/–
Regulatory maximum level exposure assessment scenario:
– for infants below 16 weeks of age: exposure calculations based on the MPL according to
Annex II to Regulation (EC) No 1333/2008 for FC 13.1.5.1 or according to Annex III to
Regulation (EC) No 1333/2008 for FC 13.1
+
Refined exposure assessment scenarios:
– exposure calculations based on the maximum or mean levels (reported use from industries) +/–
MPL: maximum permitted level.
(a): +, uncertainty with potential to cause overestimation of exposure; –, uncertainty with potential to cause underestimation of
exposure.
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maximum levels proposed are specifically intended only for food for infants below 16 weeks of age (a
clarification letter was provided by Starch Europe on 29 October 2019).
The Panel agreed to consider these proposed values as a starting point to characterise the risk of
exposure to toxic elements derived from the consumption of the food additive. The potential exposure to
these toxic elements can be calculated by assuming contamination of the additive may be up to the
maximum limits (0.05 (As), 0.01 (Cd), 0.03 (Pb) and 0.05 (Hg) mg/kg), as proposed for the revision of
the EU specifications, and then by calculation pro rata to the dietary exposure to the food additive itself.
With regard to the dietary exposure of the food additive, the Panel considered the refined
estimated exposure assessment scenario based on maximum use levels (95th percentile) for infants
below 16 weeks of age (5200 mg/kg bw per day, see Table 4), for E 1450 from carry-over into infant
formulae (100 mg/kg bw per day, see Table 5) and for toddlers (2,579 mg/kg bw per day, see
Table 6). The above-mentioned proposed maximum limits for toxic elements (0.05 (As), 0.01 (Cd),
0.03 (Pb) and 0.05 (Hg) mg/kg), combined with the estimated intakes of E 1450 (5,200, 100 and
2,579 mg/kg bw per day) could result in an exposure which can be compared with the following
reference points, or health-based guidance values (HBGVs), for the four toxic elements: a BMDL01 of
0.3–8 lg/kg bw per day for arsenic (EFSA CONTAM Panel, 2009), a total weekly intake (TWI) of
2.5 lg/kg bw for cadmium (EFSA CONTAM Panel, 2009), a BMDL01 of 0.5 lg/kg bw per day for lead
(EFSA CONTAM Panel, 2010) and a TWI of 4 lg/kg bw for mercury (EFSA CONTAM Panel, 2012).
The outcome of such an exercise illustrates the health impact that would result if the proposed
maximum limits for toxic elements were to be used: for arsenic and lead, the MOS/MOE could be as
low as 1.2 and 2.3, respectively (see Table 8). For cadmium and mercury, the exhaustion of their
HBGVs could be up to 15% and 46%, respectively.
The Panel observed that if these maximum levels were to be applied, i.e. 0.05 (As), 0.01 (Cd), 0.03
(Pb) and 0.05 (Hg) mg/kg), this would mean that the performance of the analytical method applied
should guarantee a limit of quantification (LOQ) of two-fifths of the maximum level, i.e. 0.02 (As),
0.004 (Cd), 0.012 (Pb) and 0.02 (Hg) mg/kg, as in accordance to the provisions of Commission
Regulation (EC) No 333/200719 for toxic elements in food. These LOQ values, especially for cadmium,
may be technically difficult to be achieved with the analytical techniques commonly applied for the
measurement of toxic element (e.g. ICP-MS). Of note, E 1450 is a sodium-containing food additive and
sodium inhibits ionisation efficiency in the ICP-MS; thus, a lower sensitivity would be expected.
In addition, the Panel pointed out that it should be checked whether these limits are technologically
achievable also in the food additive intended for food for population groups other than infants below
16 weeks of age, according to what declared by the interested party.
The Panel also noted that there is some uncertainty on the exact concentration of the toxic
elements reported for the 27 production batches, as the analytical data provided on the samples are
expressed as ‘less than a reporting level’, which may be assumed referring to the LOQs of the
analytical measurements, and not as measured values (with the exception for three samples in the
lead determination). Therefore, the Panel decided to perform also an estimate of the exposure to toxic
elements, derived from the food additive, considering the highest ‘less than value’ reported per each
Table 8: Exposure to toxic elements based on the maximum limits for toxic elements in SSOS
(E1450) for use in food for infants below 16 weeks of age as proposed by interested party
(Documentation provided to EFSA n. 1)
Exposure to
the additive
(mg/kg bw
per day)
MOS/MOE for As MOS/MOE for Pb % of the TWI for Cd % of the TWI for Hg
0.05 mg/kg 0.03 mg/kg 0.01 mg/kg 0.05 mg/kg
5200 (Table 4) 1.2–31 3.2 15 46
100 (Table 5) 60–1,600 166.7 0.28 0.9
2579* (Table 6) 2.3–62.5 6.5 7.2 22.4
*: In EFSA ANS Panel (2017), the highest dietary exposure to modified starches E 1404-1451 for the population above 16 weeks
was 3,053 mg/kg bw per day (toddlers, brand-loyal refined exposure assessment scenario). Therefore, the dietary exposure
to E 1450 (see Table 6) for this population group was considered in the current assessment.
19 Commission Regulation (EU) No 333/2007 of 28 March 2007 laying down the methods of sampling and analysis for the official
control of the levels of lead, cadmium, mercury, inorganic tin, 3-MCPD and benzo(a)pyrene in foodstuffs. OJ L 88, 29.3.2007,
p. 29–38.
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toxic element multiplied by an ‘uncertainty’ factor (UF) of 10 in order to cover uncertainties, such as
representativeness, homogeneity and analytical measurement uncertainty. The resulting calculated
concentration values of toxic elements (i.e. 0.5 (As), 0.1 (Cd), 0.3 (Pb), 0.5 (Hg) mg/kg), combined with
the estimated intakes of E 1450 (5,200, 100 and 2,579 mg/kg bw per day), were then compared with the
corresponding reference points or HBGVs for the four toxic elements (a BMDL01 of 0.3–8 lg/kg bw per
day for arsenic (EFSA CONTAM Panel, 2009), a TWI of 2.5 lg/kg bw for cadmium (EFSA CONTAM Panel,
2009), a BMDL01 of 0.5 lg/kg bw per day for lead (EFSA CONTAM Panel, 2010) and a TWI of 4 lg/kg bw
for mercury (EFSA CONTAM Panel, 2012)).
The health impact that would result if the highest ‘less than values’ reported, multiplied by UF of
10, for example, were to be used as maximum levels are as follows: for arsenic and lead, the MOS/
MOE could be as low as 0.12 and 0.32, respectively (see Table 9). For cadmium and mercury, the
TWIs are exceeded by factors up to 1.5 (Cd) to 4.6 (Hg).
The resulting figures show, in both exposure scenarios described (i.e. using the maximum levels as
proposed by the interested party or using the highest reported ‘less than value’ multiplied by UF of
10), that the exposure to toxic elements from the consumption of E 1450 is not marginal. Therefore,
this supports the Panel recommendation to substantially decrease the current maximum limits set for
arsenic, lead and mercury and to introduce a maximum limit for cadmium.
The Panel emphasises that the choice of the magnitude of an acceptable MOS/MOE or an
acceptable level of exceedance of the TWI from one source only as a basis to conclude on the
maximum limits for toxic elements in the specifications is in the remit of risk management. However,
the Panel noted that the MOS/MOE for arsenic and lead is very low, considering that for lead, the
reference point is based on perturbation of intellectual development in children, (who have the highest
exposure), and for arsenic, the reference point is based on carcinogenicity.
With regard to the maximum limit for octenylsuccinic acid residue, the Panel considered the
proposal by the interested party to maintain the value currently set in the EU Reg. 213/2012, i.e. not
more than 0.3%, to be adequate as it reflects the analytical levels measured in the food additive
(Documentation provided to EFSA n. 1).
With regard to the maximum limit for sulfur dioxide, the proposal by the interested party is to lower
the limit to not more than 10 mg/kg according to the analytical results obtained from the analysis of
commercial samples of the food additive. The Panel agreed with this proposal and pointed out that
sulfur dioxide is an authorised food additive (E 220) with a maximum permitted level (MPL) up to
2,000 mg/kg. In addition, under EU Reg. 1169/2011 on the provisions of food labelling information to
consumers, sulfur dioxide and sulfites are considered allergens. For prepacked foods, their presence in
a food or beverage must be indicated on the label, by its full name, when the level exceeds 10 mg/kg
or 10 mg/L (expressed as SO2). Therefore, the presence of sulfur dioxide in E 1450 as impurity, within
the proposed maximum limit, does not constitute a safety concern.
The interested party declared that the proposed maximum limits both for octenylsuccinic acid
residue and sulfur dioxide are specifically intended for food for infants below 16 weeks of age (like the
specification proposals for toxic elements). Therefore, the Panel reiterated that it should be checked
whether these limits can be technologically achievable also in food for other population groups.
The Panel noted also that the use of ingredients for infant formula and follow-on formula is
regulated in the EU by Regulation 2016/127 on infant formulae and follow-on formulae, clearly stating
(Annex II) that ‘The use of ingredients containing gluten shall be prohibited8’. Therefore, the food
Table 9: Exposure to toxic elements considering the highest ‘less than value’, multiplied by an UF of
10, reported per each toxic element in 27 batches of E 1450 (Documentation provided to
EFSA n. 1)
Exposure to the
additive
(mg/kg bw per day)
MOS/MOE for As MOS/MOE for Pb
% of the TWI for
Cd
% of the TWI
for Hg
0.5 mg/kg 0.3 mg/kg 0.1 mg/kg 0.5 mg/kg
5200 (Table 4) 0.12–3.1 0.32 146 455
100 (Table 5) 6–160 17 2.8 8.8
2579*(Table 6) 0.23–6.3 0.65 72 224
*: In EFSA ANS Panel (2017), the highest dietary exposure to modified starches E 1404-1451 for the population above 16 weeks
was 3,053 mg/kg bw per day (toddlers, brand-loyal refined exposure assessment scenario). Therefore, the dietary exposure
to E 1450 (see Table 6) for this population group was considered in the current assessment.
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additive SSOS (E 1450) should not contain gluten (only in infant formula and follow-on formula, in
accordance with Regulation 2016/127).
Overall, based on the data provided by interested parties in response to EFSA call for data16 and
the relative above considerations, the FAF Panel recommends the following revisions of the existing EU
Specifications for SSOS (E 1450) as outlined in Table 10.
Table 10: Proposal for a revised version of the existing EU Specifications for SSOS (E 1450)
Commission Regulation (EU)
No 231/2012
Comment/justification for revision
Definition Starch sodium octenyl succinate is the
sodium salt of starch esterified with
octenylsuccinic anhydride
Unchanged
Synonym SSOS Unchanged
Description White or nearly white powder or
granules or (if pregelatinised) flakes,
amorphous powder or coarse particles
Unchanged
Microscopic
observation
Passes test (if not pregelatinised) Unchanged
Iodine staining Passes test (dark blue to light red
colour)
Unchanged
Loss on drying Not more than 15.0% for cereal starch
Not more than 21.0% for potato starch
Not more than 18.0% for other starches
Unchanged
Octenylsuccinyl
groups
Not more than 3% (on an anhydrous
basis)
Unchanged
Octenylsuccinic
acid residue
Not more than 0.3% (on an anhydrous
basis)
Unchanged*
Sulfur dioxide Lowered based on the available analytical
results*
Arsenic Lowered based on the available analytical
results*
Lead Lowered based on the available analytical
results*
Mercury Lowered based on the available analytical
results*
Cadmium Included based on the available analytical
results*
Gluten Gluten free, only in infant formula and
follow-on formula, in accordance with
Commission Delegated Regulation (EU)
2016/127/EC of 25 September 2015
Included according to Commission Delegated
Regulation (EU) 2016/127/EC
Microbiological criteria introduced for reason of harmonisation
Aerobic plate count < 100 CFU/g Included based on the available information*
Yeasts < 100 CFU/g Included based on the available information*
Salmonella spp Negative in 375 g Included based on the available information*
E. coli Negative in 10 g Included based on the available information*
Cronobacter
(Enterobacter)
sakazakii
Negative in 10 g Included based on the available information*
CFU: colony-forming unit.
*: The Panel noted that the interested party has submitted data and proposals of SSOS (E 1450) samples specifically intended
for food for infants below 16 weeks of age (a clarification letter was provided by Starch Europe on 29 October 2019).
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3.6. Biological and Toxicological data
3.6.1. Absorption, distribution, metabolism and excretion studies
The following text (in italics) is from the opinion published in 2017 (EFSA ANS Panel, 2017). New
information and assessments related to the specific age group below 16 weeks of age are added in the
following paragraphs.
In vitro study
The in vitro digestibility of OSA-modified starch by porcine pancreatic and human salivary a-
amylase, a fungal (Aspergillus niger) glucoamylase and a barley b-amylase was compared with that of
the corresponding unmodified starch from which it was prepared (NSCC, 1984; cited in JECFA, 2015).
The digestibility of OSA-modified starch, measured by the rate of production of reducing substances,
ranged from 83% to 98% of that of its corresponding native starch. It was suggested that the slight
differences in the rate of digestibility were likely due to those anhydroglucose units in the starch
substituted with OSA (about 1 in 50) inhibiting the hydrolysis of the a1-4 and a1-6 bonds. The in vitro
enzyme digestibility of OSA-modified starch was comparable to that reported for other modified food
starches.
In vivo studies
The excretion of OSA and its related metabolites was analysed in 17 hospitalised infants and
children (aged 2 months–6 years) fed one of three commercial hydrolysed protein formulas containing
OSA-modified starch21 for an unspecified duration (Kelley, 1991). Random or 24-h urine samples were
collected, and urinary metabolites were identified using gas chromatography–mass spectrometry
(GC–MS). In addition, plasma samples were collected from five patients and analysed for free fatty
acids and organic acids. The results indicated that between 10% and 25% of the OSA hydrolysed from
ingested OSA-modified starch was absorbed and excreted in the urine. The average amount of OSA
absorbed was estimated to be approximately 50–70 mg/kg bw. The principal compounds identified in
the urine were OSA and at least nine metabolites that appeared to be produced from the oxidation of
OSA by a combination of microsomal and mitochondrial or peroxisomal processes. The levels of OSA
detected in the urine ranged from 121 to 1,353 mg/g creatinine, whereas urinary levels of OSA-related
metabolites ranged from 73 to 2,168 mg/g creatinine. In the plasma, measurable concentrations of
OSA (9.5–57.9 lmol/L) were detected, but no other related metabolites were detected at
concentrations higher than 1 lg/mL. Based on the molecular weight and mass fragmentation of the
nine identified metabolites associated with the excretion of OSA, the author proposed that OSA is
metabolised in infants by a combination of x-, x-1 and b-oxidation steps, similar to valproic acid.
One hundred and seven female healthy term infants (aged 2–16 days), comprising 55 infants
administered a milk-based formula containing OSA-modified starch (concentration not specified) and
52 administered a milk-based formula containing distarch phosphate modified tapioca starch (control),
were fed for 120 days ad libitum (MJNR, 1994; cited in JECFA, 2015). Urine samples collected on day
90 were analysed for OSA and related metabolites. In the infants consuming OSA-modified starch,
urinary OSA levels ranged from 0 to 1,398.6 lg/mg creatinine (mean of 546.1 lg/mg creatinine). The
concentration of 1,2,9-non-4-enetricarboxylate, a metabolite of OSA, ranged from 0 to 865.5 lg/mg
creatinine (mean of 343.8 lg/mg creatinine).
3.6.1.1. Absorption, distribution, metabolism and excretion studies in animals
A study in juvenile rats is described by the JECFA (2015). The JECFA report did not mention the
method used to measure the parent compound and the metabolites. According to JECFA, the rats
were divided into three groups (n = 4) from which group 1 received a proprietary formula, not
containing OSA20 or SSOS (E 1450),21 as control; the second group (group 2) received a proprietary
formula (formula 1) to which OSA was added (0.72 mg/mL) and the third group formula 2 which
contained SSOS (E 1450) with an OSA content of 0.42 mg/ml (0.58 fold less OSA than in group 2).
The animals received the formula once by oral application (not further specified). By comparison of the
OSA and metabolites excreted in urine after administration of OSA as such or after administration of
SSOS, it could be shown that 35% of the dose is excreted in urine when OSA is added to formula and
20 The hydrolysis product of OSA (Octenyl Succinic Acid) -modified starch, from JECFA, 2015).
21 Name used by JECFA (2015): OSA (Octenyl Succinic Acid)-modified starch.
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that 19% of the OSA-dose is excreted in the urine when SSOS (E 1450) is added (see Table 11). The
result indicates that OSA is split off from SSOS (E 1450) and that the amount of OSA which is split off
accounted to 54.3%.
Absorption, distribution, metabolism and excretion studies in humans
In a study in 17 infants and children (age 2 months to 6 years), receiving SSOS (E 1450) (reported
as OSA-modified cornstarch) containing formulas, OSA and OSA metabolites were determined in the
urine (Kelley, 1991), see summary above from EFSA ANS Panel (2017). The ratio of OSA metabolites
to OSA was not different when infants up to 4 months were compared to infants above 4 months (up
to 4 months: mean 2.4, range 0.35–4.8; above 4 months: mean 1.9, range 0.31–4.7; calculations by
the Panel), indicating no metabolic differences. The publication does not give the dose which the
infants received nor was the sampling scheme the same for all children (24 h collection in six infants;
sampling at random in 11 infants). In this publication, the excretion of glutarate and ketoglutarate in
urine was in about half of the infants above the normal values. Because of the lack of information and
the interference with the concomitant treatment of the infants, it was not possible for the Panel to
draw any conclusions on the association between the intake of SSOS (E 1450) and the elevated
excretion of glutarate and ketoglutarate. Overall, from the rat study, the conclusion can be drawn that
OSA is split off from SSOS (E 1450) and metabolised to the same metabolites as found in urine after
OSA administration. In humans, Kelley (1991) proposes that OSA is split off from SSOS (E 1450)
(reported as OSA-modified cornstarch) and then metabolised to several metabolites whereby
metabolites are produced by shortening the side chain after omega oxidation by cycles of beta
oxidation. In the study MJNR, 1994 (cited in JECFA, 2015), the excretion of OSA and of its metabolite
1,2,9-non-4-enetricarboxylate in urine indicates also that OSA is split off from SSOS (E 1450) and
metabolites are formed by omega oxidation. Comparison among different species and data comparing
young and old population were not available.
Gut microbiome
In general, when starches are reaching the caecum and colon, they are fermented by the gut
microbiome into short-chain fatty acids (SCFA). The SCFA (acetate, propionate, butyrate) are further
metabolised after absorption and have multiple actions in diverse organs where they are introduced
into the general metabolism (Hu et al., 2018). They have been reported to have a wide array of
beneficial effects (den Besten et al., 2015a,b; Canfora et al., 2015; Gonzalez-Bermudez et al., 2018).
Information specific for SSOS (E 1450) was not available.
An interplay between microbiome and the diet has been described (den Besten et al., 2013). In
infants, it is known that the microbiome depends on the mode of delivery (vaginal or caesarean), and
also on the feeding, e.g. more diverse microbiomes in formula-fed infants have been found compared
to breast-fed infants. A recent narrative review (Chong et al., 2018) confirmed these factors and
expanded them by mentioning age, diet, host genetics, antibiotic usage and the birth environment of
the infants e.g. neonatal intensive care unit (NICU). In both publications, the authors conclude that
more data are required for a better understanding of the interaction between the factors. The
Table 11: Metabolite urinary excretion in rats following the administration of a formula added with
OSA (formula 1) and to a formula containing SSOS (E 1450) (formula 2), from JECFA
(2015)
OSA* SSOS (E 1450)**
Dose (lmol/kg bw) 120 69.1
Urinary excretion lmol/24 h lmol/24 h
Tricarboxylic acid derivate of OSA 3.13  1.19 1.06  0.07
7-hydroxyacetyl succinate 0.71  0.21 0.13  0.03
6-hydroxyacetyl succinate 2.03  0.95 0.48  0.18
1,2,7-hept-4-enetricarboxylate 0.39  0.13 0.17  0.04
OSA 0.1  0.09 0.03  0.01
Excretion of OSA and metabolites (% of dose) 35  12 19  2
OSA: octenyl succinic acid; SSOS: starch sodium octenyl succinate; bw: body weight.
*: 28% (w/v) suspension of proprietary formula 1 to which OSA (0.72 mg/mL) was added.
**: Suspension of proprietary formula 2 containing SSOS (E 1450), with an OSA content of 0.42 mg/mL.
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Panel noted that changes in the composition of the gut microbiota without measuring a specific health
outcome are difficult to interpret.
3.6.2. Short-term and subchronic toxicity
The following information from short-term and subchronic toxicity studies was reviewed by the ANS
Panel in the context of the re-evaluation of the safety of modified starches (EFSA ANS Panel, 2017):
‘In a 8-week study, groups of 12 weanling albino rats (6/sex) were maintained on diets containing
64% carbohydrate ingredients consisting of 29% cellulose, with the remaining 35% consisting of
starch sodium octenyl succinate, or corn starch as a control (. . .) Rats fed the substituted starch
showed a slightly slower growth rate than control rats fed corn starch. The decreased growth rate was
associated with decreased food consumption. Efficiency of food utilisation was not affected by the test
compound.
Rats (Charles River) received a diet containing 6%, 12% or 30% starch sodium octenyl succinate
(plus cornstarch at a 30% level of the diet) or 30% cornstarch (Buttolph and Newberne, 1980) (. . .)
The animals were allowed to mate twice. The F1b generation was maintained on the same test diet as
the parents and used for the study (. . .) Twenty animals from the 30% starch sodium octenyl
succinate and control groups were killed at 30 days post-weaning, and the remainder of the animals
killed 90 days post-weaning (. . .) There was no significant effect on growth rate. Serum chemistry and
haematology were within normal levels and showed no compound-related effects. Urine chemistry
showed higher concentrations of urinary calcium and magnesium in females but not in males. Relative
organ weight data showed a trend for increased liver and kidney weight with increased concentration
of the substituted starch in the diet. There was an increased caecal weight in the animals fed 30%
starch sodium octenyl succinate in both sexes after 30 days, but this was only observed in females
after 90 days on the test diet. The only significant histological finding was an incidence of
corticomedullary mineralisation in the kidneys. The effect was more severe in females than in males,
and occurred in animals fed either the modified or unmodified starch.
In a 90-day study (Unilever, 1984; cited in JECFA, 2015), groups of 10 male and 10 female
ColworthWistar rats (. . .) the control diets for each of the OSA-modified test groups contained
unmodified starch. The modified starch diets provided approximately 37,000 mg/kg bw per day of
OSA-modified starch (. . .)
There were no differences in body weight gain, feed consumption, plasma chemistry measurements
or urine analysis parameters when comparing animals on the test diets (OSA-modified starch) with
those on the corresponding basal control diets (. . .). Similarly, no significant test article-related
changes in liver, kidney or caecum weights were observed when comparing the animals on the test
diets with those on the corresponding basal control diets. (. . .) Increased kidney weights were
observed (. . .) considered to be related to corticomedullary nephrocalcinosis. All female animals fed the
‘in-house’ purified diets exhibited corticomedullary nephrosclerosis, and it was noted that the inclusion
of OSA-modified starch did not influence its severity. Similar effects were not apparent in male rats.
The authors concluded that the inclusion of OSA-modified starch in the diet of rats for 90 days at a
concentration of 30% (approximately 37,000 mg/kg bw per day) did not adversely affect any
parameter examined, when compared with the control unmodified starch (Unilever, 1984; cited in
JECFA, 2015). The Panel agreed with this conclusion’.
3.6.3. Post-natal studies
In the evaluation of the ANS Panel in 2017 (EFSA ANS Panel (2017)) and in JECFA (2015), a study in
pups of Beagle dogs (age 5–9 days) which were dosed with 0 (water control), 5,000 or 10,000 mg/kg bw
per day of SSOS (E 1450)21 or 5,000 or 10,000 mg/kg bw per day of a control starch for 6 weeks was
described. There were no significant differences in blood chemistry, haematology or urine parameters
among groups. No deaths, gross lesions or histological findings were attributable to the treatment. The
full study report of this study was not available for evaluation by the FAF Panel.
In the former evaluation (EFSA ANS Panel, 2017) a 3-week dietary toxicity study of SSOS (E 1450)
in farm piglets was briefly described; however, the study report was not available. The Panel received
the full study report (Documentation provided to EFSA n. 3). The results of this study were also
published by Mahadevan et al. (2014).
The study was performed according to Good laboratory practice (GLP), FDA (2006), EMA (2009)
and ICH (2010). The objective of this study was to evaluate the safety of SSOS (E 1450) after 3 weeks
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of dietary administration to farm piglets starting 2 days after birth and evaluate the impact of SSOS (E
1450) on their growth. The pig was selected for use in this study because of similarity of the digestive
system between neonatal swine and human infants. The RoB Risk of Bias score (RoB) was rated as
tier 1, which indicating a low risk of bias (see Appendix C).
Domestic Yorkshire cross-bred piglets (n = 6/sex per group; body weight males 1.7–2.5 and
females 1.4–2.6 kg) were administered 500 mL/kg bw per day of milk containing 0, 2, 4 or 20 g SSOS
(E 1450) per litre (equivalent to 0, 1,000, 2,000 or 10,000 mg/kg bw per day) from post-natal day
(PND) 2 for 3 weeks. The highest dose was chosen to represent up to the regulatory limit in the EU.
To ensure that the total caloric intake was similar among groups, accounting for the decreased
digestibility of SSOS (E 1450), the control, low-dose, mid-dose and high-dose groups also received
amioca powder (control article) at levels of 8,000, 7,200, 6,400 or 0 mg/kg bw per day, respectively.
SSOS (E 1450) and amioca were added to a commercially available milk replacer. The energetic value
of the formulation was assumed to be 60 kcal/L in all test groups. The test formulations were offered
orally via a feeding bowl at a dose volume of 500 mL/kg bw per day, six times per day (~ 83.33 mL/kg
bw per dose, 3.25 h between doses). Animals were randomly assigned by sex using body weight to
the treatment groups. The first feeding of the formulation started on lactation day 2; day of arrival of
the animals at the test facility. All animals survived to scheduled necropsy on day 21, and there were
no compound-related changes in clinical observations during the study except for a decrease in growth
of the male piglets of the high-dose group. In female animals’ significant effect on body weight gain
were not observed; only one female showed a lower body weight gain in the high-dose group).
However, the Panel noted that four out of six male animals had a decrease in the body weight gain at
the high-dose and one out of six male animals in the mid-dose group. This effect was not statistically
significant; however, the change in body weight compared to the control over the entire study (study
day 1–21) was approximately 30%. The feed intake of the male piglets of the high-dose group was
decreased when compared to the control group; the difference was statistically significant on study
day 20. The Panel noted that it was unclear whether reduced palatability alone was responsible of the
reduced feed intake observed in the high-dose male group. No dose-related effects on haematology,
clinical chemistry and urine analysis were observed on study day 8 and 21. Faecal samples were
negative for parasites. Organ weights were obtained for the brain, heart, kidney, large intestine
(caecum, colon, rectum), liver, small intestine (duodenum, jejunum and ileum) and spleen. The relative
liver and kidney weights of the male piglets of the high-dose group were statistically significantly
decreased (approximately 15%). No macroscopical effects were observed at necropsy. Microscopical
examination of the organs listed above, as well as eye, including optic nerve; gall bladder; stomach;
gross lesions; lung with bronchi; pancreas; and Peyer’s patch did not show treatment-related effects.
While the authors argued that the effect on liver and kidney weight could be secondary to decreased
growth/body weight gain and/or incidental, the Panel considered the effect on relative organ weight as
treatment-related, although not adverse as no histopathological changes were observed. The authors
concluded that administration of SSOS (E 1450) in the diet for a 3-week period after birth was well
tolerated in piglets and that exposure to SSOS (E 1450) did not produce any definitive compound-
related effects and considered 10,000 mg/kg bw per day, the highest dose tested as the NOAEL. The
Panel performed a benchmark dose modelling (BMD) on body weight gain in males according to the
guidance of the Scientific Committee (EFSA Scientific Committee, 2017b) and concluded that based on
the reported data, no dose response could be identified.
In summary, in the animal studies evaluated by the ANS Panel (EFSA ANS Panel, 2017), no
indication of significant toxic effects of SSOS were observed. However, the FAF Panel considered that
the 8-week study in weanling rats and the 90-day rat study were not appropriate for the evaluation of
SSOS as a food additive in food for infants below 16 weeks of age. In the study in pups of Beagle
dogs up to 10,000 mg SSOS/kg bw per day for 6 weeks effects on body weight and food consumption
were not described. The full study report was not available to the Panel and, therefore, a reference
point could not be derived from this study.
The results of the post-natal study in piglets were considered by the FAF Panel as the most suitable
animal data for the evaluation of SSOS as food additive in food for infants below 16 weeks of age.
However, due to the absence of effects in female animals and a lack of a dose-response in the effect
on body weights of male piglets, the Panel could not identify a reference point for the hazard
characterisation of SSOS based on the data from this study.
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3.6.4. Clinical studies
The following six clinical studies were submitted by the interested business operators in response to
the call for data launched by EFSA: Ahrens et al. (2018); Borschel and Kajzer (2011) (documentation
provided to EFSA n. 3); Borschel et al. (2013) (full study report provided by the interested business
operators, documentation provided to EFSA n. 7); Burks et al. (2008) (full study report provided by
the interested business operators, documentation provided to EFSA n. 8 and 9); Fleddermann et al.
(2014) and Scalabrin et al. (2009) (full study report provided by the interested business operators,
documentation provided to EFSA n. 10).
The Panel noted that according to the study reports or the publications on the studies, the studies
were not aimed to investigate the influence of SSOS (E 1450) on the development of weight or on the
tolerability.
The reviewers gave identical RoB scores for all studies (see Figure 3 and Appendix D for further
details). Only minor inconsistencies on the scoring for some of the questions/elements were noted and
clarified. Five of the studies were allocated to tier 3 (high risk of bias) (Ahrens et al., 2018; Borschel
and Kajzer, 2011; Borschel et al., 2013; Burks et al., 2008; Scalabrin et al., 2009). The study of
Fleddermann et al. (2014) was allocated to tier 2 (moderate risk of bias). Studies allocated to a RoB
tier 3 could only be used as supporting evidence and are briefly described here. The elements
considered for RoB appraisal by the reviewers are summarised in Figure 3.
The aim of the study of Ahrens et al. (2018); was described as follows: ‘A high protein content
of non-hydrolysed infant formula exceeding metabolic requirements can induce rapid weight gain and
obesity. Hydrolyzed formulas with too low protein (LP) content may result in inadequate growth. The
aim of this study was to investigate non inferiority of partial and extensively hydrolysed formulas (pHF,
eHF) with lower hydrolysed protein content than conventionally, regularly used formulas, with or
without synbiotics for normal growth of healthy term infants’. Four hundred and two infants were
randomised to four treatment groups; LP-formula containing partially hydrolysed proteins (1.9 g
protein/100 kcal) with or without synbiotics, LP-eHF formula with synbiotics or formula with regular
protein content (2.3 g protein/100 Kcal). The primary endpoint was the average daily weight gain over
84 days. The trial was set up as a non-inferiority trial with a non-inferiority margin of - 3.5 g/day,
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Ahrens et al., 2018 ++ - - + - - ++ + 3
Borschel and Kajzer, 2011 ++ ++ + -- + + ++ -- 3
Borschel et al., 2013 ++ ++ - -- - + - -- 3
Burks et al., 2008 ++ ++ ++ -- + + ++ -- 3
Fleddermann et al. 2014 + + + + - + ++ + 2
Scalabrin et al., 2009 + ++ - -- - + + + 3
Definitely low risk of bias (++), Probably low risk of bias (+), Probably high risk of bias (), Definitely high risk of
bias ().
Figure 3: ‘Risk of bias summary’ modified from the Cochrane RoB tool, see Appendix D for further
details
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resulting in a total weight difference of - 294 g as being equivalent with the control. In the publication
and the supplementary information, the content of the formulas is given without mentioning SSOS (E
1450) as one of the components of the formula. According to the information from the interested
business operators, the SSOS (E 1450) content was in the control formula and in
the experimental formulae (Specialised Nutrition Europe, clarification letter dated 19 September 2019).
All tested formulas showed non-inferiority compared with the control. The main deficiencies of the
study were that the composition in proteins content differed between, on the method of measurement
and on the loss of participants above 20% which is seen as invalidating study results (Genaidy et al.,
2007). The study was allocated to tier 3 (high risk of bias).
In the study report from Borschel and Kajzer (2011) (documentation provided to EFSA n. 3), it
is not mentioned that SSOS (E 1450) was used but only starch. In a communication (Abbott,
communication dated March 2019), it was reported that SSOS (E 1450) in two of the formulations
used (EF-1 and EF-2) in this study was 1.9 g/L (as fed). The study was a randomised, multicentre,
controlled, double-blinded, parallel group study. One hundred and sixty-eight healthy term infants
between 0 and 8 days of age were randomised to receive ad libitum one of the three study formulas,
control product without SSOS (E 1450) and one product containing SSOS (E 1450). ‘The purpose of
this study was to evaluate the tolerance of infants fed experimental casein hydrolysate-based formulas
containing alternate CHO sources, compared to a commercially available
casein hydrolysate, based formula. The primary endpoint was MRSC (mean rank stool consistency)
from Study Visit 1 to Study Visit 3 (approximately 28 days of age) (cited from the study report).’
Further outcomes included weight and height and adverse event monitoring. The main deficiency of
the study was the loss of participants above 20% (25% in EF-1 and 22% in EF-2) which is seen as
invalidating study results (Genaidy et al., 2007) and the lack of quantitative information on the content
of the different ingredients in the formula, in particular of SSOS (E 1450) in EF-1 and EF-2 in the study
report. The study was allocated to tier 3 (high risk of bias).
The main objective of the study by Borschel et al. (2013) was described as follows: ‘The present
study was designed to assess the growth of healthy term infants fed an amino acid -based formula
versus an extensively hydrolyzed casein-based formula in a randomized controlled trial that met robust
criteria proposed for evaluating the ability of a formula to support growth of infants.’ In the
publication, it is declared that the extensively hydrolysed casein-based formula contained 1.6% SSOS
(E 1450). This extensively hydrolysed casein-based formula was compared to an amino acid-based
formula which besides the difference in the source of proteins also contained different sources for the
fat content and no SSOS. The randomised, double-blind parallel group study was performed in 213
infants entering the study between 0 and 9 days old; 107 infants were randomised to the amino acid-
based formula whereas 106 infants were randomised to the formula containing 1.6% SSOS (E 1450).
The study duration was 112 days. The formulas were given ad libitum and were the sole source of
nutrition throughout the study. The primary endpoint was weight gain between 14 and 112 days of
age. Secondary endpoints included length, head circumference, study formula intake, daily stool
number, MRSC and serum albumin concentration. Seventy-nine infants (37%) dropped out, with similar
demographic characteristics between groups. The numbers of infants who finished the study early
because of intolerance symptoms were similar. The group receiving SSOS (E 1450) had a significantly
greater number of daily stools and average MRSC. This finding may be explained by the differences in
protein composition between the two study formulae. No statistically significant differences between
groups in weight, length, head circumference or mean serum albumin concentration were noted. The
Panel noted that 40 of the 106 infants randomised to the formula containing 1.6% SSOS (E 1450)
dropped out from the study, 21 of them because of intolerance which was not further specified. From
the 66 infants which completed the study, no adverse events were noted, the SSOS (E 1450)
consumption being a mean of 2.35 g/kg bw per day over 112 days. The main deficiencies of the study
were the loss of participants above 20% which is seen as invalidating study results (Genaidy et al.,
2007) and the difference in nutritional composition others than SSOS (E 1450) between the formulae.
The study was allocated to tier 3 (high risk of bias).
In the study by Burks et al. (2008) for which a report was made available by interested business
operators, the aim is described as follows: ‘The primary objective of this study was to compare weight
gain from 14 to 120 days in term infants fed one of two study formulas: 1) a commercially available
casein hydrolysate formula (Control formula or CF); or 2) an experimental amino acid-based formula
(Test Formula, or TF). Secondary objectives were to evaluate length gain and head circumference
gain; formula intake acceptance; and tolerance; and incidence of adverse events among infants
consuming the study formulas. An additional secondary objective was to verify that the resulting
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plasma amino acid profile of infants fed the test formula was similar to that of infants fed the control
formula and to published values of breastfed infants.’ In the study report, the composition of the two
formulas is given. However, it is not mentioned whether the formulas contained SSOS (E 1450). The
Panel was later informed by the interested business operators that both formulas contained SSOS (E
1450) with a content of (control formula) and (experimental formula) without
further documentation (Specialised Nutrition Europe, clarification letter dated 6 December 2019). A
difference in length increase and final length (0.113  0.003 cm/day in control group vs. 0.107 
0.003 cm in the experimental group, p = 0.030; 64.3  0.4 cm in control group vs. 63.4  0.4 in the
experimental group) was noted, these differences are not biologically relevant. The main deficiencies
of the study were that the composition concerning the source for proteins/amino acids differed
between the formulas and loss of participants above 20% which is seen as invalidating study results
(Genaidy et al., 2007). The study was allocated to tier 3 (high risk of bias).
The Panel noted that the study from Burks et al., 2008 included a trial assessing the
hypoallergenicity of infants formulae, this part of the study was considered not relevant for the
assessment of SSOS (E 1450) and was not considered further.
The objective of the study by Fleddermann et al., 2014; was the following: ‘In the present
study we compared growth and blood biochemistry of infants fed a modified infant formula with
reduced protein content and rich in ALAB (a-lactalbumin) as well as added LC-PUFA (long chain
polyunsaturated fatty acid) to a formula with standard protein content and without LC-PUFA, and a
reference group of breastfed infants. The randomized controlled trial aimed to assess the suitability of
a reduced-protein ALAB and LC-PUFA containing formula focusing on growth velocity, adverse events,
markers of fatty acids and protein status and energetic efficiency in infants until the age of 10 days.’ In
the study publication, the composition of the two formulas is given. However, it is not mentioned
whether the formulas contained SSOS (E 1450). The Panel was later informed by the interested
business operators that both formulas contained SSOS with a content of
without further documentation (Specialised Nutrition Europe,
clarification letter dated 19 September 2019). In the method section, a primary endpoint is not
mentioned; however, the statistical consideration was based on weight gain. Two hundred and thirteen
infants were randomised to the two treatments and the duration of the study was from 1 month to 4
months. Weight gain was not statistically different between the intervention and the control group.
The main deficiencies of the study were that the composition of proteins and fat differed between the
formulas and that the information on the content of SSOS (E1450) is not given in the publication. The
study was allocated to tier 2 (moderate risk of bias) and provides limited evidence for the safe use of
SSOS in a relatively low concentration of .
The primary objective of the study of Scalabrin et al. (2009) was described as follows: ‘The
primary objective was to compare the rate of weight gain (g/day) from 14 to 120 days of age in
healthy, term infants fed 1 of 3 study formulas. Secondary objectives were to compare formula groups
with respect to other growth parameters (length and head circumference [HC] growth rates), formula
intake and tolerance, adverse events (AEs), blood lipids, allergic sensitization, and antibody response
to immunizations commonly given to infants.’ In the study report, the composition of the two formulas
is given However, whereas the content of carbohydrate is given, it is not specified whether one or
more of the formulas contained SSOS (E 1450). The study tested three different formulas in 276
infants (14 days old), from which 220 infants completed the study after 120 days of exposure. The
study was planned to assess the influence on growth and on the tolerance of adding Lactobacillus
rhamnosus to a hydrolysed infant formula. According to an information of the interested business
operators, two of the formulas contained SSOS (E 1450).The three formulas were as follows: EHF, a
formula without Lactobacillus rhamnosus, but with ; EHF-LGG, a formula with
Lactobacillus rhamnosus, and with and PHF-LGG, a formula with Lactobacillus
rhamnosus, without SSOS (E 1450) (Specialised Nutrition Europe, clarification letter dated 6 December
2019). The study was not intended to investigate the tolerability of SSOS (E1450). Hence, the control
group in the study received . In evaluating the data of the study, the
Panel considered PHF-LGG, a formula with Lactobacillus rhamnosus, without SSOS (E 1450) as the
control group and the EHF-LGG group, a formula with Lactobacillus rhamnosus, and with
as the experimental group. No difference in weight, length and head circumference
was observed. A difference was noted in stool frequency with lower frequency in the group receiving
the formula with Lactobacillus rhamnosus, without SSOS (E 1450) (p < 0.05) and in firmness of stools
with firmer stools in the group receiving the formula with Lactobacillus rhamnosus, without SSOS (E
1450) (p < 0.005). It is to be noted that in the group receiving the formula containing SSOS (E 1450)
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relatively more infants dropped out (33%) than in the group receiving the formula containing no SSOS
(E 1450) (21%), which may indicate a reduced tolerability of the formula with
. The main deficiencies of the study were that the composition concerning the lack of
information on SSOS in the study report and loss of participants above 20% (21% EHF group, 26%
PHF-LGG group, 33% EHF-LGG group), which is seen as invalidating study results (Genaidy et al.,
2007). The study was allocated to tier 3 (high risk of bias).
The levels in the formulas given as interventions in the clinical trials described above were
calculated by the Panel, please refer to Appendix E for a detailed description on how the calculations
were performed.
3.6.5. Post-market monitoring
No reports in the scientific and medical literature were identified during the reporting period by
Abbott Nutrition (Documentation provided to EFSA by a SNE Member).
No additional cases of adverse reactions were found by a literature search submitted by the
interested business operators (Documentation provided to EFSA n. 3).
3.7. Discussion
This assessment is a follow-up addressing data gaps previously identified during the re-evaluation
for SSOS (E 1450) and the safety in the special subpopulation of infants below 16 weeks of age (EFSA
ANS Panel, 2017), see also Appendix B.
The process involved the publication of a dedicated call for data, allowing all interested business
operators to provide the requested information for completing the assessment and to confirm that the
additive is used in FC 13.1.5.1 and is also present in infant formula (13.1.1) as a carry-over resulting
from the authorised use in accordance with Annex III to Regulation (EC) No 1333/2008. Further
consideration on the use as food additive in food according to FC 13.1.5.1 and FC 13.1.5.2 (dietary
foods for babies and young children for special medical purposes as defined in Directive 1999/21/EC)
in infants above 16 weeks of age and young children up to 3 years was also requested. The data
submitted comprise technical information on impurities of the additive, formulation examples for
products on the market, use levels in relevant infant formulae, toxicity data such as a report on a
3-week dietary study on piglets, clinical data and post-marketing surveillance reports. No adequate
data were submitted by the interested business operators which can serve as the basis to assess the
safety of SSOS (E 1450) in the use according to FC 13.1.5.1 and 13.1.5.2 for uses in food for infants
above 16 weeks and young children.
The Panel considered it feasible to amend a number of specifications based on the analytical
evidence submitted in response to the call for data. This refers to lowering existing limits for SO2, toxic
elements, as well as introducing new specifications for cadmium and microbiological criteria for the
food additive.
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A study in juvenile rats, described in JECFA (2015), showed that the relative absorption of OSA
(bound and unbound) from SSOS (E 1450) resulted in 53% (mean of excretion of four metabolites and
the parent compound OSA), indicating that in the rat at least half of the SSOS (E 1450) is hydrolysed
to OSA.
In infants between 2 months and 5 years, the ratio of OSA metabolites to OSA was not different
when infants up to 4 months were compared to infants above 4 months indicating no metabolic
differences. The metabolites are excreted via urine. In general, when starches are reaching the
caecum and colon, they are fermented by the gut microbiome into SCFA. The SCFA (acetate,
propionate, butyrate) are further metabolised after absorption and have multiple actions in diverse
organs where they are introduced into the general metabolism (Hu et al., 2018). The publication of
Kelley (1991) reported that the excretion of glutarate and ketoglutarate in urine was in about half of
the infants above the normal values. However, when analysing the data, there was no indication that
infants up to 4 months were more prone to have elevated levels. No further quantitative information is
available on the fate of SSOS (E 1450) in infants up to 4 months as compared to older infants,
adolescents or adults. Comparison among different species and data comparing young and old
population were not available.
An interplay between microbiome and the diet has been described (den Besten et al., 2013). In
infants, it is known that the microbiome depends on the mode of delivery and also on the feeding, e.g.
more diverse microbiomes in formula-fed infants have been found compared to breast feed infants. A
recent narrative review (Chong et al., 2018) confirmed these factors and expanded them by
mentioning age, diet, host genetics, antibiotic usage and the birth environment of the infants (e.g.
NICU). In both publications, the authors conclude that more data are required for a better
understanding of the interaction between the factors and what is necessary to maintain intestinal
homoeostasis in terms of microbiome in the different population groups. The Panel noted that changes
in the composition of the gut microbiota without measuring a specific health outcome are difficult to
interpret.
In the animal studies evaluated by the ANS Panel (EFSA ANS Panel, 2017), no indication of
significant toxic effects of SSOS was observed. However, the FAF Panel considered that the 8-week
study in weanling rats and the 90-day rat study were not appropriate for the evaluation of SSOS as a
food additive in food for infants below 16 weeks of age. In the study in pups of Beagle dogs up to
10,000 mg SSOS/kg bw per day for 6 weeks, effects on body weight and food consumption were not
described. The full study report was not available to the Panel and, therefore, reference point could
not be derived from this study.
The results of the post-natal study in piglets were considered by the FAF Panel as the most suitable
animal data for the evaluation of SSOS as food additive in food for infants below 16 weeks of age.
However, due to the absence of effects in female animals and a lack of a dose-response in the effect
on body weights of male piglets, the Panel could not identify a reference point for the hazard
characterisation of SSOS based on the data from this study.
Further to the call for data, five references and one study report from clinical trials conducted in
infants below 16 weeks of age were submitted by interested business operators. Following requests for
additional information, original study reports were made available for three of the published clinical
trials, so that for four of them, the assessment could be based on the full study reports.
However, in only one study, the content of SSOS (E 1450) in the formula was clearly stated and
could be calculated to be 1.6%; in the remaining studies, no information concerning the content of
SSOS (E 1450) in the formulae was found, and in the study reports, no exact information on the SSOS
(E 1450) content was given. The Panel was later provided with the information about the content of
SSOS (E 1450) in the studies.
The Panel noted that even the primary full study reports did not contain information on the content
of SSOS (E 1450) in the formulae and that the SSOS (E 1450) levels provided by interested business
operators in 2019 were not accompanied by certificates, which could be a confirmation of the SSOS
levels. The lack of information on the level of SSOS (E 1450) can be explained by the fact that none of
the studies was planned to investigate the influence of SSOS (E 1450) on body weight and its
tolerability in infants below 16 weeks of age. Hence, in none of the studies, the composition of the
formula of the control group was identical to the formula containing the SSOS (E1450). Additionally, in
some of the studies, the SSOS (E1450) was contained in the formula of the control group in nearly the
same concentration as in the formula of the experimental group.
The six studies were appraised for their risk of bias applying an assessment tool modified from the
OHAT RoB tool (NTP-OHAT, 2015, 2019). The elements considered for the appraisal are described in
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the Appendix D to this opinion, as well as the decision rule for assigning the studies to tiers of
reliability. Five of the studies were allocated to tier 3 (high risk of bias) (Ahrens et al., 2018; Borschel
and Kajzer, 2011; Borschel et al., 2013; Burks et al., 2008; Scalabrin et al., 2009). The study of
Fleddermann et al. (2014) was allocated to tier 2 (moderate risk of bias). Concerning the outcome of
the assessment of RoB of the clinical studies, it is general agreement that studies allocated to tier 3
can only be used as supportive evidence. Insofar, the study of Fleddermann et al. (2014), allocated to
tier 2 would be the only study which could serve as study providing main evidence.
In a case report series from 1991, no adverse effects specific to the SSOS (E 1450) in children were
identified. Specific information about post-marketing monitoring data for formula with high SSOS
(E 1450) content (1.6% and higher) is not available.
In EFSA ANS Panel opinion (2017), the Panel concluded that the available data did not allow for an
adequate assessment of the safety of the use of SSOS (E 1450) in ‘dietary foods for special medical
purposes and special formulae for infants’ (food category 13.1.5.1) and in foods belonging to food
category 13.1.5.2, in infants and young children consuming these foods at the presently authorised
maximum use levels of 20,000 or 50,000 mg/kg, respectively. After the call for data, no studies and no
data were submitted by the interested business operators.
Dietary exposure to SSOS (E 1450) from its use as a food additive was assessed based on (1) MPLs
set out in the EU legislation (defined as the regulatory maximum level exposure assessment scenario)
and (2) the reported use levels (defined as the refined exposure assessment scenario), (3) the levels
in the formulas given as interventions in the clinical trials considered in this assessment.
Both scenarios (1) and (2) are based on the recommended consumption levels from SC Guidance
(EFSA Scientific Committee, 2017a) which recommends values of 200 and 260 mL formula18/kg bw per
day as conservative mean and high-level consumption values for 14–27 days old infants.
For infants below 16 weeks of age consuming FSMP (FC 13.1.5.1), mean exposure in the regulatory
maximum level exposure assessment scenario was estimated at 4,000 mg/kg bw per day while at the
high level was estimated at 5,200 mg/kg bw per day. As the maximum level reported by industry was
equal to the MPL of 20,000 mg/kg, exposure estimates are the same for the refined scenario based on
maximum levels of use provided by the interested business operators. For the scenario using the mean
of the reported use levels from industry, exposure estimates were of 1,676 mg/kg bw per day at the
mean and 2,179 mg/kg bw per day at the high level of consumption.
Exposure to SSOS (E 1450) estimated for the clinical trials described above were
,
in the Borschel and Kajzer (2011) study, the average intake of
SSOS was between 262 and 362 mg/kg bw per day depending on the formulae and the day of the
study;
For infants below 16 weeks of age consuming infant formulae which could contain SSOS (E 1450)
from carry-over (FC 13.1.1), in the regulatory maximum level exposure assessment scenario, mean
exposure was estimated at 220 mg/kg bw per day while at the high level was estimated at 286 mg/kg
bw per day. For the scenario using the maximum level provided by industry, mean exposure was
estimated at 77 mg/kg bw per day while at the high level was estimated at 100 mg/kg bw per day.
The scenario using the mean of the reported use levels from industry, mean exposure was estimated
12 mg/kg bw per day at the mean and 16 mg/kg bw per day at the high level.
The Panel emphasised that the refined exposure estimates are based on information provided on
the reported level of use of SSOS (E 1450). If actual practice changes, these refined estimates may no
longer be representative and should be updated.
In conclusion, when considering the available information to set a reference point, studies in
healthy infants would be the preferred data source. However, most of them (five of the six studies
provided) had low internal validity, reflected in the high risk of bias (tier 3). The study with a moderate
risk of bias (tier 2) had very low content of SSOS in the formulae used in both study arms of
. In addition, in all the studies, the composition of the control formula, used without SSOS
(E 1450), differed from the composition of the experimental formula with SSOS (E 1450). The
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Panel explored the possibility to compare the studies concerning growth with non-randomised
comparisons (i.e. comparisons to historical controls, such as comparisons to growth reference charts
the data of which are of observational nature), but considered that the available data on these growth
reference charts were not sufficiently informative for the European population. Hence, the
Panel concluded that a reference point could not be derived from the clinical studies. The
Panel considered whether the results from the piglet study could be used for identifying a reference
point but had to note that the uncertainty surrounding the results precludes deriving a reference point
from this study.
On the other hand, both data sources did not clearly indicate an adverse effect due to SSOS. In the
former evaluation, the ANS Panel concluded that there was no safety concern for the use of modified
starches as food additives at the reported uses and use levels and that there was no need for a
numerical ADI for the general population (EFSA ANS Panel, 2017). Based on this and the newly
available data, the FAF Panel considered that for exposure to SSOS of infants below 16 weeks, there is
no indication for a concern when within the range reported in the clinical studies (up to 2,725 mg/kg
bw per day).
When extrapolating the conclusion above to the safety assessment of the food additive when used
in FCs 13.1.5.1 and 13.1.5.2 in food for infants above 16 weeks of age and young children, the
Panel considered that for exposure to SSOS of infants above 16 weeks and young children, there is no
indication for a concern when within the range reported in the clinical studies (up to 2,725 mg/kg bw
per day).
4. Conclusions
Due to the low internal validity of the clinical studies, the Panel concluded that a reference point
could not be derived from them. The Panel noted that the uncertainty surrounding the results of the
piglet study precludes deriving a reference point from this study.
On the other hand, both data sources did not clearly indicate an adverse effect due to SSOS. Given
the available data, the Panel concluded that at use levels of SSOS in food for infants below 16 weeks
within the range reported in the clinical studies (up to 2,725 mg/kg bw per day), there is no indication
for safety concern and reiterated the conclusion of the ANS Panel (EFSA ANS Panel, 2017) that there
was no need for a numerical ADI.
When extrapolating the conclusion above to the safety assessment of the food additive when used
in FCs 13.1.5.1 and 13.1.5.2 in food for infants above 16 weeks of age and young children, the
Panel considered that there is no indication for safety concern also for these uses within the range
reported in the clinical studies.
The Panel noted that at the reported use levels, the estimates of exposure could exceed the higher
end of the exposure in the clinical trials.
Having considered the analytical data submitted by the interested business operators, the
Panel concluded that these data support a revision of the existing specifications.
5. Recommendation
The Panel recommends that:
• The European Commission considers revising the MPL of SSOS (E 1450) in FCs 13.1.5.1 and
13.1.5.2.
• The European Commission to revise the current specifications for the food additive SSOS
(E 1450) in line with the proposals made in Table 10.
6. Documentation as provided to EFSA
1) Starch Europe, 2019. Submission of data in response to the call for technical and
toxicological data on starch sodium octenyl succinate (E 1450) for uses as a food additive
in foods for all population groups including infants below 16 weeks of age submitted on
January 2019.
2) SNE (Specialised Nutrition Europe), 2019. Response from Specialised Nutrition Europe of
EFSA call for data on starch sodium octenyl succinate (E 1450) authorised as a food additive
in support of the risk assessment for infants below 16 weeks of age. January 2019.
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3) Abbott Nutrition Research & Development, 2019. Submission of data in response to the call
for technical and toxicological data on starch sodium octenyl succinate (E 1450) for uses as
a food additive in foods for all population groups including infants below 16 weeks of age
submitted on January and February 2019.
4) Mead Johnson, 2019. Submission of data in response to the call for technical and
toxicological data on starch sodium octenyl succinate (E 1450) for uses as a food additive
in foods for all population groups including infants below 16 weeks of age. January 2019.
5) HiPP, 2019. Submission of data in response to the call for technical and toxicological data
on starch sodium octenyl succinate (E 1450) for uses as a food additive in foods for all
population groups including infants below 16 weeks of age. January 2019.
6) United Pharmaceuticals, 2019. Submission of data in response to the call for technical and
toxicological data on starch sodium octenyl succinate (E 1450) for uses as a food additive
in foods for all population groups including infants below 16 weeks of age. January 2019.
7) SNE (Specialised Nutrition Europe), 2020. Final report of Borschel, MW 2001. Growth of
infants fed an elemental medical food - A masked, randomized, parallel growth study of
healthy term infants fed an elemental medical food or a protein hydrolysate formula.
Submitted on January 2020.
8) SNE (Specialised Nutrition Europe), 2020. Final report of Berseth, 2006. The effects on
growth and development of an elemental formula fed to term infants. Submitted on
January 2020.
9) SNE (Specialised Nutrition Europe), 2020. Final report of Scalabrin, 2006. Double-blind,
placebo-controlled trial of an amino acid-based formula versus Neocate® in children with
cow’s milk allergy. Submitted on January 2020.
10) SNE (Specialised Nutrition Europe), 2020. Final report of Scalabrin, 2008. The effects on
growth and tolerance of healthy, term infants fed hydrolyzed formulas with Lactobacillus
rhamnosus GG. Submitted on January 2020.
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Abbreviations
ADI acceptable daily intake
AEs Adverse events
ALAB alpha-lactalbumin
ANS Panel EFSA Panel on Food Additives and Nutrient Sources added to Food
AOAC Association of Official Analytical Chemists
As Arsenic
BMD benchmark dose
BMDL lower confidence limit of the benchmark dose
bw body weight
CAS Chemical Abstract Service
Cd Cadmium
CF control formula
CFU Colony forming unit
CHO Carbohydrates
CONTAM Panel EFSA Panel on Contaminants in the Food Chain
DG Sante Directorate General for Health and Food safety
E 1450 SSOS (starch sodium octenyl succinate)
EF Experimental formula
e(E)HF extensively hydrolysed formula
EMA European Medicines Agency
EU European Union
FAF Panel EFSA Panel on Food Additives and Flavourings
FAO/WHO Food and Drug Organisation/World Health Organisation
FC Food category
FDA Food and drug administration
FSMP Food for special medical purposes
GLP Good laboratory practice
HBGVs Health based guidance values
HC head circumference
Hg Mercury
ICH International Conference on Harmonisation
ICP-MS inductively coupled plasma mass spectrometry
JECFA Joint FAO/WHO Expert Committee on Food Additives
LC long chain
LOQ Limit of quantification
LP Low protein
Mintel GNPD Mintel’s Global New Products Database
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MOE margin of exposure
MOS margin of safety
MPL maximum permitted levels
MRSC mean rank stool consistency
NICU Neonatal intensive care unit
NOAEL no-observed-adverse-effect level
OHAT Office of Health Assessment and Translation
OSA octenyl succinic acid
Pb Lead
p(P)HF partially hydrolysed formula
PND postnatal day
PUFA Polyunsaturated fatty acids
RoB Risk of bias
SC Scientific Committee of EFSA
SCFA short-chain fatty acids
SNE Specialised Nutrition Europe
SSOS starch sodium octenyl succinate
TAMC total anaerobic microbial count
TF test formula
TWI total weekly intake
TYMC total combined yeast and mould count
UF Uncertainty factor
WHO World Health Organization
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Appendix A – Summary of the reported use levels (mg/kg or mg/L as appropriate) of food additive (E 1450)
provided by industry
Food
category
number
Food category
name
E-number MPL
Number
of
samples
Mean of
typical
usage
levels
Minimum of
typical usage
levels
Maximum of
typical usage
levels
Maximum
usage level
Comments,
restrictions
Provided by
13.1.1 Infant formulae as
defined by Commission
Directive Commission
Delegated Regulation
(EU) 2016/127
E 1450 1,100 (as
carry-over)
12 –
13.1.5.1 Dietary foods for
infants for special
medical purposes and
special formulae for
infants
E 1450 with
thickeners
20,000 1 –
13.1.5.1 Dietary foods for
infants for special
medical purposes and
special formulae for
infants
E 1450 20,000 2 –
13.1.5.1 Dietary foods for
infants for special
medical purposes and
special formulae for
infants
E 1450 with
thickeners
20,000 2 –
13.1.5.1 Dietary foods for
infants for special
medical purposes and
special formulae for
infants
E 1450 20,000 5 –
13.1.5.1 Dietary foods for
infants for special
medical purposes and
special formulae for
infants
E 1450 20,000 1 –
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Appendix B – Data requested in the call for data (Call for technical and
toxicological data on starch sodium octenyl succinate (E 1450) for uses as
a food additive in foods for all population groups including infants below
16 weeks of age.22
Kind of data Data requested in the call for data
Responses from
interested business
operators
Comment
A. Information regarding the follow-up of the conclusions and the recommendations of the EFSA
ANS Panel opinion on the safety starch sodium octenyl succinate (E 1450) as a food additive
1.Technical
data
Analytical data on current levels of
current levels of lead, mercury and
arsenic in commercial samples of the
food additive
No analytical data and no
proposal for specifications
for use in food for other
population groups than
infants below the age of
16 weeks were provided
No analytical data and no
proposal for specifications
for use in food for other
population groups than
infants below the age of
16 weeks were provided
as requested in part A.1
of the call for data
(clarification letter by
Starch Europe dated 29
October 2019)
The lowest technologically achievable
level for lead, mercury, cadmium and
arsenic in order to adequately define
their maximum limits in the
specifications
The lowest technologically achievable
level for sulfur dioxide
The lowest technologically achievable
level for octenylsuccinic acid residue
No analytical data and no
proposal for specifications
for use in food for other
population groups than
infants below the age of
16 weeks were provided
Specifications unchanged
on the basis of the
received data, see
Section B.1
Because of both the botanical origin and
the polysaccharidic nature of starch
sodium octenyl succinate (E 1450), it can
be a substrate of microbiological
contamination. Data should be provided
demonstrating the absence of Salmonella
spp. and Escherichia coli and on the
lowest total aerobic microbial count
(TAMC) and total combined yeast and
mould count (TYMC) that can be
reached
No analytical data and no
proposal for specifications
for use in food for other
population groups than
infants below the age of
16 weeks were provided
No analytical data and no
proposal for specifications
for use in food for other
population groups than
infants below the age of
16 weeks were provided
as requested in part A.1
of the call for data
(clarification letter by
Starch Europe dated 29
October 2019)
2. Toxicological
data
According to the conclusions and
recommendations in the Scientific
opinion on the re-evaluation of starch
sodium octenyl succinate (E 1450) as a
food additive by the EFSA ANS
Panel published in 2017, the generation
of additional data to assess the potential
health effects of starch sodium octenyl
succinate (E 1450) when used as a food
additive in ‘dietary foods for infants for
special medical purposes and special
formulae for infants’ (Food category
13.1.5.1) and in ‘dietary foods for babies
and young children for special medical
purposes as defined in Directive 1999/
21/EC’ (Food category 13.1.5.2) was
recommended. These requirements will
be addressed as outlined in section B.2
No data submitted When extrapolating the
conclusion for the uses in
FC 13.1.5.1 for infants
below 16 weeks of age to
the FCs 13.1.5.1 and
13.1.5.2 in food for
infants above 16 weeks of
age and young children,
the Panel considered that
there is no safety concern
also for these uses within
the range reported in the
clinical studies
22 Available online: http://www.efsa.europa.eu/en/consultations/call/180718-4) and responses from interested parties
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Kind of data Data requested in the call for data
Responses from
interested business
operators
Comment
3. Literature
search
Literature searches should be conducted
relevant for the safety evaluation of
starch sodium octenyl succinate (E 1450)
for all uses in foods for all population
groups from 02/05/2017 up to the date
of the data submission, as described in
the Guidance for submission for food
additive evaluations (see its section 5.3)
Received Assessed, further
follow-up
B. Information required for the risk assessment of starch sodium octenyl succinate (E 1450) for
uses in foods for infants below 16 weeks of age
1. Technical
data
Information on the levels of use of
starch sodium octenyl succinate (E 1450)
in special formulae for infants of that
age under special medical conditions (FC
13.1.5.1) and in infant formulae (FC
13.1.1) when added as food additive in
nutrients used in these formulae
Received Assessed, no further
follow-up
Information on the fate and the reaction
products of starch sodium octenyl
succinate (E 1450) in special formulae
for infants of that age under special
medical conditions (FC 13.1.5.1) and in
infant formulae (FC 13.1.1) when added
as food additive in nutrients used in
these formulae
Received Assessed, no further
follow-up
Information on particular specification
requirements for identity and purity of
starch sodium octenyl succinate (E 1450)
(e.g. with respect content in lead and
other heavy metals, sulfur oxide and
octenylsuccinic acid) when used in
special formulae for infants of that age
under special medical conditions (FC
13.1.5.1) and when added in infant
formulae (FC 13.1.1) as food additive in
nutrients used in these formulae.
Analytical data on toxic elements in the
final special formulae for infants below
16 weeks of age need to be provided
when no legal limit. Analytical data on
toxic elements in the final special
formulae for infants below 16 weeks of
age need to be provided when no legal
limit
In addition, data should be provided
demonstrating the
absence of Cronobacter (Enterobacter)
sakazakii in the food additive
Received Assessed, no further
follow-up
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Kind of data Data requested in the call for data
Responses from
interested business
operators
Comment
Toxicological
data
The full report of the randomised,
multicentre, double-blind, good clinical
practice (GCP)-compliant trial (Borschel
and Kajzer, 2011)
Received Assessed, no further
follow-up
The full report of the repeated dose
study in neonatal piglets (Mahadevan
et al., 2014)
Received Assessed, no further
follow-up
Updated post-marketing surveillance
report since 2016 on undesired and
adverse reactions (e.g. flatulence,
gastrointestinal discomfort, changes of
stool frequencies and consistency and
diarrhoea), indicating the ages and other
relevant data of the exposed infants and
young children and the use level of
starch sodium octenyl succinate (E 1450)
in the marketed products, where the
FSMPs are already in use
Received Assessed, no further
follow-up
Published and unpublished case reports
(e.g. available nutrivigilance data) on
undesired and adverse effects, including
e.g. flatulence, gastrointestinal
discomfort, changes of stool frequencies
and consistency and diarrhoea,
associated with the oral administration of
starch sodium octenyl succinate in any
form to infants and young children
Received Assessed, no further
follow-up
3. Literature
searches
Literature searches should be conducted
relevant for the safety evaluation of
starch sodium octenyl succinate (E 1450)
when used in foods for infants below 16
weeks of age up to the date of the data
submission, as described in the Guidance
for submission for food additive
evaluations (its Section 5.3)
Received Assessed, no further
follow-up
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Appendix C – Risk of bias/Internal validity for Experimental Animal Studies (modified from NTP-OHAT, 2015,
2019)
Decision rules
The ratings of the key and non-key questions (++, +, –, ) will be integrated to classify the studies in tiers from 1 to 3 corresponding to decreasing
levels of internal validity.
Tier 1:
• All the key questions are scored +/++
AND
• No more than one non-key question is scored –
AND
• No non-key question is scored 
Tier 2:
• All the other combinations not falling under tier 1 or 3
Tier 3:
• Any question is scored 
OR
• More than one key question is scored –
Outcome of the RoB assessment
Assessed study: A 3-week dietary toxicity study of octenyl succinic anhydride (OSA) in farm piglet. Abbott Nutrition, study 126-658; Study report 21
November 2012, Study completion 26 November 2012 (Documentation provided to EFSA n. 3).
Outcome of the assessment:
Question Domain of bias Rating (++, +, , ) Rating of the study
Reviewer 1
Rating of the study
Reviewer 2
1. Was the
administered dose
or exposure level
adequately
randomised?
Key question
Selection ++ If the method is described and it is adequate ++
The method is
described, and it is
adequate
++
Standard, by weight,
measured value
randomisation
procedure
+ If the authors only indicate that randomisation was done but do
not describe the method
– No mentioning of randomisation
 Direct evidence of no randomisation
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Question Domain of bias Rating (++, +, , ) Rating of the study
Reviewer 1
Rating of the study
Reviewer 2
2. Was allocation
to the study
groups adequately
concealed?
Selection ++ Properly concealed and described how concealment was
performed
++
Properly concealed
and described how
concealment was
performed
++
Animal number to be
used in the Provantis
data collection system
assigned to each
animal
+ Mentioning that concealment was performed; + is also appropriate
if non-concealment does not influence the outcome
 If non-concealment does influence the outcome (measurements
with a subjective part (e.g. preparation of fat pads, observation of
behaviour))
 If non-concealment does influence the outcome to a very
important part (subjective measurements)
3. Were
experimental
conditions identical
across study
groups?
Key question
Performance ++ Experimental conditions described and identical across study
groups (feeding, water supply, bedding, day/night cycle;
temperature; humidity)
++
Experimental
conditions described
and identical across
study groups (feeding,
water supply, bedding,
day/night cycle;
temperature;
humidity)
++
According to the Study
Director minor
deviations did not
impact the study
results
+ Incomplete description of experimental conditions; + is also
appropriate if lack of information does not influence the outcome
 If lack of information does influence the outcome
 If factors clearly indicate that treatment conditions were
different does influence the outcome to a very important part
4. Was the
research personnel
blinded to the
study group?
Key question
Performance ++ If there is direct evidence that the research personnel did not
know what group animals were allocated to, and it is unlikely that
they could have broken the blinding of allocation
+
Not reported and lack
of adequate allocation
concealment would
not appreciably affect
the allocation of
animals to different
study groups (e.g.
methods used which
do not have a
subjective component)
+
Not reported, unless
answer to question 2
implies blinding.
Specifically, the
blinding of the
pathologist is not
mentioned. However,
no macroscopic or
microscopic treatment-
related findings were
reported. Therefore,
this should not be a
major issue
+ If not reported and lack of adequate allocation concealment
would not appreciably affect the allocation of animals to different
study groups (e.g. methods used which do not have a subjective
component)
 If not reported and lack of adequate allocation concealment
would appreciably affect the allocation of animals to different study
groups (e.g. methods used which have a subjective component)
 If there is direct evidence that it was possible for the research
personnel to know what group animals were allocated to, or it is
likely that they could have broken the blinding of allocation
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Question Domain of bias Rating (++, +, , ) Rating of the study
Reviewer 1
Rating of the study
Reviewer 2
5. Were outcome
data complete
without attrition or
exclusion from
analysis?
Attrition/exclusion ++ There is direct evidence that loss of animals was adequately
addressed, and reasons were documented when animals were
removed from a study
OR
Missing data have been imputed using appropriate methods
(ensuring that characteristics of animals are not significantly
different from animals retained in the analysis)
++
Direct evidence that
loss of animals was
adequately addressed,
and reasons were
documented when
animals were removed
from a study
++
+ There is indirect evidence that loss of animals was adequately
addressed, and reasons were documented when animals were
removed from a study
OR
It is deemed that the proportion lost would not appreciably bias
results. This would include reports of no statistical differences in
characteristics of animals removed from the study from those
remaining in the study
OR
There is insufficient information provided about loss of animals
(record ‘NR’ as basis for answer), but it is considered that this does
not have an impact on the validity of the study
 There is indirect evidence that loss of animals was unacceptably
large and not adequately addressed (e.g. if unexplained loss is
equal or more than 25%)
OR
There is insufficient information provided about loss of animals
(record ‘NR’ as basis for answer) and it is suspected that this would
have an impact on the validity of the study
Note: Unexplained inconsistencies between materials and methods
and results sections (e.g. inconsistencies in the numbers of animals
in different groups) could be an example of indirect evidence
 There is direct evidence that loss of animals was unacceptably
large and not adequately addressed
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Question Domain of bias Rating (++, +, , ) Rating of the study
Reviewer 1
Rating of the study
Reviewer 2
6. Can we be
confident in the
exposure
characterization?
Key question
Detection ++ There is direct evidence that the substance was sufficiently
described and consistently administered (e.g. with the same method
and timeframe) across treatment groups.
++
There is direct
evidence that the
substance was
sufficiently described
and consistently
administered (e.g.
with the same method
and timeframe) across
treatment groups.
++
Analytical report in
Annex B
+ There is indirect evidence that the substance was sufficiently
described and consistently administered (i.e. with the same method
and time frame) across treatment groups.
OR
There is insufficient information provided about description and
administration of the substance (record ‘NR’ as basis for answer),
but it is considered that this does not have an impact on the validity
of the study.
 There is indirect evidence that the substance was not sufficiently
described and was not consistently administered (e.g. with the
same method and timeframes) across groups.
OR
There is insufficient information provided about description and
administration of the substance (record ‘NR’ as basis for answer)
and it is suspected that this has an impact on the validity of the
study.
 There is direct evidence that the substance was not sufficiently
described and/or was not consistently administered (e.g. with the
same method and time frames) across groups.
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Question Domain of bias Rating (++, +, , ) Rating of the study
Reviewer 1
Rating of the study
Reviewer 2
7. Can we be
confident in the
outcome
assessment?
Key question
Detection
Element 1
Was the outcome assessed at the
same length of time (i.e. day and/
or time of day) after initial
exposure in all study groups?
(remember to take into
consideration the endpoints
assignments)
Element 2
Was a reliable and sensitive animal
model used for investigating the
test compound and selected end
points?
Element 3
Was the number of animals per
dose group appropriate?
Element 4
Was the number of animals per
sex in each cage appropriate for
the study type and animal model?
Element 5
Was the timing and duration of
administration of the test
compound appropriate?
Element 6
Were reliable and sensitive test
methods used for investigating the
selected end points?
Element 7
Were the measurements collected
at suitable time points in order to
generate sensitive, valid and
reliable data?
++ There is direct evidence
+ It is deemed that deviation would not appreciably bias results. OR
There is insufficient information provided, but it is considered that
this does not have an impact on the validity of the study.
 There is insufficient information provided (record ‘NR’ as basis for
answer) and it is suspected that this has an impact on the validity
of the study.
 There is direct evidence for a deviation
Decision rules for the final assessment of 7
if element 4  results in 
if element 4  results in 
if more than 3 elements ++ and the remainder + or  (exception
element 4) results in ++,
if less than 3 elements ++ and the remainder + or  (exception
element 4) results in +
if more than 3 elements + and the remainder  (exception
element 4) results in +
if less than 3 elements + and the remainder + or  (exception
element 4) results in 
if more than 3 elements  (excluding element 4) results in 
if more than 3 elements  (including element 4) results in 
if less than 3 elements (excluding element 4)  results in 
if less than 3 elements (including element 3)  results in 
if more than 3 elements  results in 
++
All elements: ++
Animal number was
low but acceptable
++
All elements: ++
Animal number was
low but acceptable
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Question Domain of bias Rating (++, +, , ) Rating of the study
Reviewer 1
Rating of the study
Reviewer 2
8. Were all
outcomes
measured
according to the
methodology
section reported?
Selective reporting ++ There is direct evidence that all of the study’s measured
outcomes (apical and intermediate) outlined in the protocol,
methods, abstract, and/or introduction that are relevant for the
evaluation have been reported
This would include outcomes reported with sufficient detail to be
included in meta-analysis or fully tabulated during data extraction
and analyses had been planned in advance
++ ++
+ There is indirect evidence that all of the study’s measured
outcomes (apical and intermediate) outlined in the protocol,
methods, abstract and/or introduction that are relevant for the
evaluation have been reported. This would include outcomes
reported with insufficient detail such as only reporting that results
were statistically significant (or not)
OR
Analyses that had not been planned in advance (i.e. retrospective
unplanned subgroup analyses) are clearly indicated as such and it is
deemed that the unplanned analyses were appropriate and selective
reporting would not appreciably bias results (e.g. appropriate
analyses of an unexpected effect)
OR
There is insufficient information provided about selective outcome
reporting (record ‘NR’ as basis for answer) but it is considered that
this does not have an impact on the validity of the study.
 There is indirect evidence that all of the study’s measured
outcomes (apical and intermediate) outlined in the protocol,
methods, abstract and/or introduction that are relevant for the
evaluation have not been reported
OR
There is indirect evidence that unplanned analyses were included
that may appreciably bias results
OR
There is insufficient information provided about selective outcome
reporting (record ‘NR’ as basis for answer) and it is suspected that this has
an impact on the validity of the study
Note: Unexplained inconsistencies betweenmaterials andmethods and
results/abstract or summary sections (e.g. inconsistencies in the numbers
of animals in different groups) could be an example of indirect evidence
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Question Domain of bias Rating (++, +, , ) Rating of the study
Reviewer 1
Rating of the study
Reviewer 2
 There is direct evidence that not all of the study’s measured
outcomes (apical and intermediate) outlined in the protocol,
methods, abstract and/or introduction that are relevant for the
evaluation have not been reported
In addition to not reporting outcomes, this would include reporting
outcomes based on composite score without individual outcome
components or outcomes reported using measurements, analysis
methods or subsets of the data that were not prespecified or
reporting outcomes not prespecified, or that unplanned analyses
were included that would appreciably bias results
9. Were statistical
methods
appropriate?
Other sources of bias ++ There is direct evidence that the statistical methods seem
appropriate and were clearly reported (adequate treatment of
multiple testing)
++
There is direct evidence
that all of the study’s
measured outcomes
(apical and
intermediate) outlined
in the protocol,
methods, abstract and/
or introduction that are
relevant for the
evaluation have been
reported
This would include
outcomes reported
with sufficient detail to
be included in meta-
analysis or fully
tabulated during data
extraction and analyses
had been planned in
advance
++
Methods are clearly
reported and seem to
be acceptable+ Statistical methods were not clearly reported but it may be
inferred from other information that they were appropriate
OR
There is insufficient information provided about statistical methods
(record ‘NR’ as basis for answer), but it is considered that this does
not have an impact on the validity of the study.
 Statistical methods were not clearly reported but it may be
inferred from other information that they were not appropriate
OR
There is insufficient information provided about statistical methods
(record ‘NR’ as basis for answer) and it is suspected that this has an
impact on the validity of the study
 There is direct evidence that the statistical methods applied
were inappropriate
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Summary of the RoB
++ + – –
Key question (No) 1, 3, 6, 7
1, 3, 6, 7
4, 8, 9
4, 8, 9
– –
Non-key question (No) 2
2
5
5
– –
Outcome/Tier 1
1
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Appendix D – Risk of bias/Internal validity for the clinical studies (modified from to NTP-OHAT, 2015, 2019)
Decision rules
The ratings of the key and non-key questions (++, +, , ) will be integrated to classify the studies in tiers from 1 to 3 corresponding to decreasing
levels of internal validity.
Tier 1:
• All the key questions are scored +/++
AND
• No more than one non-key question is scored –
AND
• No non-key question is scored 
Tier 2:
• All the other combinations not falling under tier 1 or 3
Tier 3:
• Any question is scored – 
OR
• More than one key question is scored –
Elements considered in the assessment
Question Rating Explanation for expert judgment
1. Was the
administered dose or
exposure level
adequately
randomised?
Key question
++ There is direct evidence that subjects (or clusters) were allocated to any study group including controls using a method with a
random component. Acceptable methods of randomisation include referring to a random number table, using a computer random
number generator, coin tossing, shuffling cards or envelopes, throwing dice, or drawing of lots (Higgins and Green, 2011).
Restricted randomisation (e.g. blocked randomisation) to ensure particular allocation ratios will be considered low risk of bias.
Similarly, stratified randomisation and minimisation approaches that attempt to minimise imbalance between groups on significant
prognostic factors (e.g. body weight) will be considered acceptable
+ There is indirect evidence that subjects (or clusters) were allocated to study groups using a method with a random component
(i.e. authors state that allocation was random, without description of the method used)
OR
It is deemed that allocation without a clearly random component during the study would not appreciably bias results. For
example, approaches such as biased coin or urn randomisation, replacement randomisation, mixed randomisation and maximal
randomisation may require consultation with a statistician to determine risk-of-bias rating (Higgins and Green, 2011)
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Question Rating Explanation for expert judgment
NR There is insufficient information provided about how subjects (or clusters) were allocated to study groups
 There is indirect evidence that subjects (or clusters) were allocated to study groups using a method with a non-random
component
NOTE: Non-random allocation methods may be systematic but have the potential to allow participants or researchers to
anticipate the allocation to study groups. Such ‘quasi-random’ methods include alternation, assignment based on date of birth,
case record number, or date of presentation to study
 There is direct evidence that subjects (or clusters) were allocated to study groups using a non-random method including
judgement of the clinician, preference of the participant, the results of a laboratory test or a series of tests, or availability of the
intervention (Higgins and Green, 2011)
2. Was the allocation to
study groups
adequately concealed?
++ There is direct evidence that at the time of recruitment the research personnel and subjects did not know what study group
subjects were allocated to, and it is unlikely that they could have broken the blinding of allocation until after assignment was
complete and irrevocable. Acceptable methods used to ensure allocation concealment include central allocation (including
telephone, web-based and pharmacy-controlled randomisation); sequentially numbered drug containers of identical appearance;
sequentially numbered, opaque, sealed envelopes; or equivalent methods
+ There is indirect evidence that the research personnel and subjects did not know what study group subjects were allocated to
and it is unlikely that they could have broken the blinding of allocation until after recruitment was complete and irrevocable
OR
It is deemed that lack of adequate allocation concealment would not appreciably bias results (e.g. some crossover designs)
NR There is insufficient information provided about allocation to study groups
 There is indirect evidence that at the time of recruitment it was possible for the research personnel and subjects to know what
study group subjects were allocated to, or it is likely that they could have broken the blinding of allocation before assignment
was complete and irrevocable
NOTE: Inadequate methods include using an open random allocation schedule (e.g. a list of random numbers); assignment
envelopes used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered);
alternation or rotation; date of birth; case record number; or any other explicitly unconcealed procedure. For example, if the use
of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed
 There is direct evidence that at the time of recruitment it was possible for the research personnel and subjects to know what
study group subjects were allocated to, or it is likely that they could have broken the blinding of allocation before recruitment
was complete
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Question Rating Explanation for expert judgment
3. Were the research
personnel and human
subjects blinded to the
study group during the
study?
++ There is direct evidence that the subjects and research personnel were adequately blinded to study group, AND it is unlikely that
they could have broken the blinding during the study. Methods used to ensure blinding include central allocation; sequentially
numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes; or equivalent methods
+ There is indirect evidence that the subjects and research personnel were adequately blinded to study group, AND it is unlikely
that they could have broken the blinding during the study
OR
There is direct evidence for no blinding during the study (including where it was not possible to implement) AND it is deemed
that no blinding would appreciably bias results BUT bias minimising measures have been adequately implemented
OR
It is deemed that lack of adequate blinding or no blinding during the study would not appreciably bias results (e.g. controls
unlikely to behave differently for factors other than sodium intake) (e.g. cross-over)
NR There is insufficient information provided about blinding to study group during the study (including possible breaking and
minimising measures)
 There is indirect evidence that it was possible for research personnel or subjects to infer the study group AND it is deemed that
lack of adequate blinding or no blinding during the study would appreciably bias results (e.g. no comparable treatment of
controls, including not comparable exposure to factors other than the interventions of interest; differential behaviour) AND no
bias minimising measures have been adequately implemented
 There is direct evidence for lack of adequate blinding of the study group (including no blinding or incomplete blinding) of
research personnel and subjects AND it is deemed that lack of adequate blinding or no blinding during the study would
appreciably bias results (e.g. no comparable treatment of controls, including not comparable exposure to factors other than the
interventions of interest, differential behaviour) AND no bias minimising measures have been adequately implemented
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Question Rating Explanation for expert judgment
4. Were outcome data
complete without
attrition or exclusion
from analysis?
Key question
++ There is direct evidence that there was no loss of subjects during the study and outcome data were complete
OR
Loss of subjects (i.e. incomplete outcome data) was adequately addressed and reasons were documented when human subjects
were removed from a study or analyses. Review authors should be confident that the participants included in the analysis are
exactly those who were randomised into the trial. Acceptable handling of subject attrition includes: very few missing outcome
data (e.g. less than 10% in each group (Genaidy et al., 2007)) AND reasons for missing subjects unlikely to be related to
outcome (for survival data, censoring unlikely to be introducing bias) AND missing outcome data balanced in numbers across
study groups, with similar reasons for missing data across groups (i.e. unlikely to be related to exposure)
OR
Analyses (such as intention-to-treat analysis) in which missing data have been imputed using appropriate methods (ensuring that
the characteristics of subjects lost to follow up or with unavailable records are described in identical way and are not significantly
different from those of the study participants)
NOTE: Participants randomised but subsequently found not to be eligible need not always be considered as having missing
outcome data) (Higgins and Green, 2011)
+ There is indirect evidence that loss of subjects (i.e. incomplete outcome data) was adequately addressed and reasons were
documented when human subjects were removed from a study
OR
It is deemed that the proportion lost to follow-up would not appreciably bias results (e.g. less than 20% in each group in parallel
studies (Genaidy et al., 2007)). This would include reports of no statistical differences in characteristics of subjects lost to follow
up or with unavailable records from those of the study participants. Generally, the higher the ratio of participants with missing
data to participants with events, the greater potential there is for bias. For studies with a long duration of follow-up, some
withdrawals for such reasons are inevitable
NB: For crossover designs, this may be less of an issue
NR There is insufficient information provided about numbers of subjects lost to follow-up
 There is indirect evidence that loss of subjects (i.e. incomplete outcome data) was unacceptably large (e.g. greater than 20% in
each group in parallel studies (Genaidy et al., 2007)) and not adequately addressed
 There is direct evidence that loss of subjects (i.e. incomplete outcome data) was unacceptably large and not adequately
addressed (e.g. greater than 20% in each group in parallel studies (Genaidy et al., 2007)). Unacceptable handling of subject
attrition includes: reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or
reasons for missing data across study groups (i.e. likely to be related to the exposure); or potentially inappropriate application of
imputation
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5. Can we be confident
in the exposure
characterisation?
Key question
++ There is direct evidence that the exposure (including compliance with the treatment, if applicable) was independently
characterised
AND that exposure was consistently administered (i.e. with the same method and time frame) across treatment groups
+ There is indirect evidence that the exposure (including compliance with the treatment, if applicable) was independently
characterised
AND there is indirect evidence that exposure was consistently administered (i.e. with the same method and time-frame) across
treatment groups
NR There is insufficient information provided to judge the exposure characterisation
 There is indirect evidence that the exposure (including compliance with the treatment, if applicable) was assessed using poorly
validated methods (e.g. FFQs, spot urine etc.)
OR
There is indirect evidence that the exposure assessment was probably biased
 There is direct evidence that the exposure (including compliance with the treatment, if applicable) was assessed using poorly
validated methods (e.g. FFQs, spot urine etc.)
OR
There is direct evidence that the exposure assessment was biased
6. Can we be confident
in the outcome
assessment?
Key question
++ There is direct evidence that the outcome was assessed using well-established methods (e.g. for office BP: according to a clearly
described methodology, including e.g. repeated measurements per visit, trained technician, resting period before each
measurement)
AND
There is direct evidence that the outcome assessors were adequately blinded to the study group, and it is unlikely that they
could have broken the blinding prior to reporting outcomes
+ There is indirect evidence that the outcome was assessed using acceptable methods (i.e. deemed valid and reliable but not the
gold standard) OR it is deemed that the outcome assessment methods used would not appreciably bias results
AND
There is indirect evidence that the outcome assessors were adequately blinded to the study group, and it is unlikely that they
could have broken the blinding before reporting outcomes OR it is deemed that lack of adequate blinding of outcome assessors
would not appreciably bias results
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NR There is insufficient information provided about blinding of outcome assessors or the method of measurement
 There is indirect evidence that the outcome assessment method is an unacceptable method
OR
There is indirect evidence that it was possible for outcome assessors to infer the study group before reporting outcomes
 There is direct evidence that the outcome assessment method is an unacceptable method
OR
There is direct evidence for lack of adequate blinding of outcome assessors (including study subjects if home BP is the outcome),
including no blinding or incomplete blinding
7. Were all measured
outcomes reported?
++ There is direct evidence that all of the study’s measured outcomes (primary and secondary) outlined in the protocol, methods,
abstract and/or introduction (that are relevant for the evaluation) have been reported
+ There is indirect evidence that all of the study’s measured outcomes (primary and secondary) outlined in the methods, abstract,
and/or introduction (that are relevant for the evaluation) have been reported
OR
Analyses that had not been planned in advance (i.e. retrospective unplanned subgroup analyses) are clearly indicated as such
and it is deemed that the unplanned analyses were appropriate and selective reporting would not appreciably bias results (e.g.
appropriate analyses of an unexpected effect). This would include outcomes reported with insufficient detail such as only
reporting that results were statistically significant (or not)
NR There is insufficient information provided about selective outcome reporting
 There is indirect evidence that all of the study’s measured outcomes (primary and secondary) outlined in the methods, abstract
and/or introduction (that are relevant for the evaluation) have not been reported
OR
There is indirect evidence that unplanned analyses were included that may appreciably bias result
 There is direct evidence that all of the study’s measured outcomes (primary and secondary) outlined in the methods, abstract
and/or introduction (that are relevant for the evaluation) have not been reported. In addition to not reporting outcomes, this
would include reporting outcomes based on composite score without individual outcome components or outcomes reported using
measurements, analysis methods or subsets of the data (e.g. subscales) that were not prespecified or reporting outcomes not
prespecified, or that unplanned analyses were included that would appreciably bias results
www.efsa.europa.eu/efsajournal 57 EFSA Journal 2020;18(8):5874
Opinion on the re-evaluation of starch sodium octenyl succinate (E 1450)
Question Rating Explanation for expert judgment
8. Were there no other
potential threats to
internal validity?
NOTE:
Baseline
characteristics should
be appraised only if
Q1 (randomisation) was
rated with ++/+ and Q2
(allocation
concealment)
was rated with ++/+/NR
++ There is evidence that variables, other than the exposure and outcome, did not differ between groups during the course of the
intervention in a way that could bias results
AND, in case randomisation is rated ‘probably low’/’definitely low’ RoB and allocation concealment is rated ‘probably
low’/‘definitely low’ RoB or ‘not reported’:
There is no evidence of differences in baseline characteristics
OR
There is no information on both BUT no concern
+ 1. There is evidence that variables, other than the exposure and outcome, differed between groups during the course of the intervention
AND it is deemed that these differences would not appreciably bias results (no concern or adequately addressed by analysis)
AND, in case randomisation is rated ‘probably low’/’definitely low’ RoB and allocation concealment is rated ‘probably low’/’definitely low’
RoB or ‘not reported’:
There is evidence that reported variables differed between groups at baseline
AND
It is deemed that these differences would not appreciably bias results (no concern or adequately addressed by analysis)
OR
2. There is evidence that variables, other than the exposure and outcome, did not differ between groups during the course of the
intervention in a way that could bias results
AND, in case randomisation is rated ‘probably low’/’definitely low’ RoB and allocation concealment is rated ‘probably low’/’definitely low’
RoB or ‘not reported’:
There is evidence that reported variables differed between groups at baseline
AND
It is deemed that these differences would not appreciably bias results (no concern or adequately addressed by analysis)
OR
3. There is evidence that variables, other than the exposure and outcome, differed between groups during the course of the intervention.
AND It is deemed that these differences would not appreciably bias results (no concern or adequately addressed by analysis)
AND, in case randomisation is rated ‘probably low’/’definitely low’ RoB and allocation concealment is rated ‘probably low’/’definitely low’
RoB or ‘not reported’:
There is no evidence of differences in baseline characteristics
OR
There is no information BUT no concern
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 There is no information on baseline characteristics AND/OR there is no information about differences between groups during
the course of the intervention
AND
There is concern
 There is evidence that variables, other than the exposure and outcome, differed between groups during the course of the
intervention
AND
It is deemed that these differences appreciably biased results (there is concern (e.g. not adequately addressed by analysis))
OR, in case randomisation is rated ‘probably low’/’definitely low’ RoB and allocation concealment is rated ‘probably low’/’definitely
low’ RoB or ‘not reported’:
There is evidence that reported variables differed between groups at baseline
AND
It is deemed that these differences appreciably biased results (there is concern (e.g. not adequately addressed by analysis))
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Appendix E – Estimated exposure levels in the clinical trial
Study (authors, year) Preparation
Consumed amount (mg/kg bw per day)
Mean or range* High level
Borschel and Kajzer (2011)
(documentation provided to
EFSA n. 3)
EF-1 351.2
EF-2 341.6
Borschel et al. (2013) 2,142.5–2,724.9
Ahrens et al. (2018) Control
LPpHF
LPpHF + Syn
LPeHF + Syn
Burks et al. (2008) Control
Experimental
Fleddermann et al. (2014) Control
Experimental
Scalabrin et al. (2009)** Preparation 1
Preparation 2
*: A range is given in cases where consumption could be calculated for several periods in the study otherwise means are
calculated.
**: No consumption data were given in this study and the EFSA default consumption data were used and mean and high level
exposure was calculated.
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